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ABSTRACT 
 
This study deals with the discovery and characterization of EXN6 and EXN11 as novel tumor-
associated proteins and promising therapeutic targets for cancer at high morbidity and mortality. 
These proteins were discovered in the context of an immuno-histochemistry (IHC) screening of a 
collection of approximately 1600 murine polyclonal antibodies towards membrane/secreted 
human proteins on tissue microarrays (TMA) containing cancerous and normal sample specimens 
of breast, colon, lung, ovary and prostate (5 patients per cancer). Both proteins were over-
expressed in more cancer types, with concomitant negligible expression in corresponding normal 
samples.  
An expanded IHC analysis on 50 samples per cancer confirmed that EXN6 is mainly present at 
abnormal levels in breast and ovary cancers (40 and 35%) while it is less frequently found in colon 
and lung cancer (less than 10%). Concerning EXN11, it is mainly detected in colon cancer (40%). 
Most importantly, EXN11 is expressed in hepatic metastasis from colon cancer, suggesting that 
this protein could be important for tumor progression and dissemination.  
 
A molecular and biological characterization of the two proteins was undertaken to understand 
whether these proteins could be exploited as molecular targets for therapeutic interventions. 
Concerning EXN6, results showed that it is endogenously expressed and surface exposed in 
different breast and ovary cancers cell lines, as confirmed by gene silencing. Knock down of 
EXN6 expression significantly affects relevant cancer processes in vitro, such as cell invasiveness 
and proliferation, thus providing the first evidence that this protein could be a potential therapeutic 
target. Five highly specific monoclonal antibodies (mAbs) towards EXN6 were generated, able to 
bind the surface of EXN6 positive cells, as judged by FACS and confocal microscopy. 
Interestingly these antibodies are efficiently internalized by cancer cells, a property that makes 
them amenable for the generation of antibody-drug-conjugates (ADC). In agreement with this, 
both antibodies are capable to drive a toxin-conjugated secondary antibody into cancer cells and 
induce cell lysis. Moreover, one of them also shows ADCC activity. Thanks to these encouraging 
results, efficacy studies are ongoing to test the ability of the anti-EXN6 mAbs to prevent tumor 
formation or progression in mouse cancer models, either as naked antibodies or as ADCs.  
 
Concerning EXN11, an expression profile analysis in human cancer epithelial, stromal and 
endothelial cells showed that the protein is normally endogenously expressed at very low level 
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while it is specifically up-regulated by hypoxia. Interestingly, this protein is secreted and partially 
associated with the exosomial fraction, suggesting that it could be released in the systemic 
circulation of oncologic patients and it may act in an endocrine way. Moreover, we showed that 
EXN11 exerts pro-angiogenetic activities on human differentiated endothelial cells by stimulating 
their motility, invasiveness and capability to form capillary-like networks, whereas it does not 
stimulate endothelial progenitor cells. Finally, EXN11 promotes vascularization in vivo in the 
mouse matrigel sponge assay. Experiments are ongoing to understand the role of EXN11 in cancer 
angiogenesis.  
 
Overall, this study highlights the relevance of EXN6 and EXN11 as potential cancer markers and 
molecular targets for novel therapies. The identification of the molecular ligands and the cellular 
pathways in which they are involved, currently under investigation, would significantly facilitate 
the design of specific drugs. MAbs offer interesting therapeutic opportunities for both proteins. 
Concerning EXN6, this study already contributed to this aspect by providing novel anti-EXN6 
mAbs with therapeutic potential.  
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1. INTRODUCTION 
1.1 Cancer, the disease 
Cancer represents the second and third cause of death in the developed countries and worldwide, 
respectively. Cardiovascular and infectious diseases are the other two major killer diseases. 
However, in the near future, cancer is expected to become the leading cause of death. The first 
reason is that deaths from cardiovascular and infectious diseases are declining, thanks to the 
scientific achievements in the understanding of the pathogenic mechanisms and risk factors 
associated with these diseases, and to the overall improvement of sanitary conditions. The second 
reason is due to the genetic mutations that occur every day, because of metabolic reactions and of 
environmentally induced cellular damages, which accumulate because of the extension of human 
life span. The National Cancer Institute of the United States of America (NCI) recently estimated 
that a 2013 newborn has a 40% possibility to get a cancer during his/her life. In the last decade, 
malignancies affecting breast, colon, ovary, prostate and lung cancers had the highest incidence 
and mortality, and are therefore considered as the “five killers”. Prostate, breast and lung cancers 
have been the tumors at the highest incidence, followed by colorectal and ovary cancers. Table 1 
reports the epidemiological data of the five tumors in 18 SEER geographic areas of the United 
States for the first six months of 2013 (http://www.cancer.gov/statistics/). 
 
Table I – Expected Incidence and mortality rates of major tumors in the USA in 2013 
Cancer 
Estimated 
new cases 
% of all 
new cases 
Estimat
ed 
death 
% of all 
cancer 
deaths 
Incidence 
per 
100,000 
Mortality 
per 
100,000 
Prevalence 
Breast 232,340 14.1 39,620 6.9% 123.6 22.6 2,829,041 
Colon 
and rectal 
142,820 8.6 50,830 8.8 45.0 16.4 1,154,481 
Lung and 
bronchus 
228,190 13.7 159,480 27.5 61.4 49.5 399,431 
Prostate 238,590 14.4 29,720 5.1 152 23 2,617,682 
Ovary 22,240 1.3 14,030 2.4 12.5 8.1 186,138 
 
Despite cancer is still as a devastating disease, cancer-associated deaths are constantly declining 
since 1995 (Figure 1), thanks to the significant progress in the understanding of tumor biology, 
improved and early diagnosis, and the identification of appropriate therapies.  
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Figure 1 – Cancer death rates in the United States from 1975 to 2010 
(NCI:http://seer.cancer.gov/csr/1975_2010/) 
 
This favorable trend will probably continue and improve in the next years. In an optimistic view 
of the future of cancer prevention and treatment, cancer will be a sort of “chronic disease” that 
will allow oncologic patients to live with a good quality of life with for several years, similarly to 
what now occurs with diabetes, hypertension, and other once deadly pathologies.    
 
The fight against cancer is based on the combined action of: i) prevention, ii) early diagnosis, iii) 
accurate surgery, and iv) optimized and personalized therapy (1) 
- Prevention – A number of environmental factors and personal behaviors are risk factors 
for cancer, with higher relevance for specific pathologies such as smoking and lung 
cancer, ultraviolet light exposure and melanoma, excessive meat assumption and colon-
rectal cancer. Moreover, different microorganisms are responsible for aggressive forms of 
cancer, such as HBV and HCV for hepatocarcinomas, HPV for cervical cancers, and 
Helocobacter pylori whose chronic infection can lead to stomach cancer. Thus, a proper 
surveillance of healthcare and correction of wrong behaviors aimed at reducing the 
exposure and prolonged contact with these tumorigenic agents should have a profound 
effect on cancer control.  
- Early and accurate diagnosis – Most cancer deaths are the consequence of the cancer 
progression and disseminated metastases deriving from primary tumors that are generally 
refractory to the current therapies. Therefore, the success of a cancer treatment strongly 
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depends upon the ability to diagnose and treat cancer before the metastasis process has 
started. Moreover, an important aspect is the characterization of the cancer aggressiveness 
and metastatic potential that has an impact in the clinicians’ decision on the most 
appropriate treatments. In fact, it is now well established that tumors fall into three classes 
(Http://cancer.gov/cancertopics): i) low invasive and metastatic cancers which remain in 
such a state during the life time of the patients; ii) highly aggressive cancers with a high 
metastatic potential that, in most cases have already disseminated by the time of diagnosis; 
iii) cancers of intermediate grade that have the potential to disseminate. Presently, a 
common way of thinking is that only the last group of cancers is really worthy of 
treatment. Indeed, death rates associated to indolent low invasive tumors is low. In 
addition, it has been shown that surgery may even provoke dormant cancers to become 
clinically apparent, or even aggressive. Concerning the highly aggressive cancers, they are 
generally refractory to the available therapies, whose toxicity sometimes overcome their 
palliative curative effects. Finally, the treatment of tumors with intermediate 
aggressiveness have a high probability to lead to a long-term, even relapse-free response. 
However, at present, the ability of differentiating tumors is still rudimental and all classes 
are treated similarly, with limited success and high socio-sanitary economical costs.  
Cancer markers are tumor-associated molecules that enable oncologists to distinguish 
different type of markers, characterize them for their severity, and monitor their 
progression. Moreover, markers could allow to discriminate cancers that are likely to 
respond to specific therapy, thus allowing a more tailored treatment of oncologic patients. 
Despite the incredible effort of academic and industrial research centers in the cancer 
markers field, due to the heterogeneity and complexity of cancer, the number of clinically 
relevant markers is still limited.  
Surgery – Surgery is still the first medical intervention to fight cancer and will remain a 
key therapeutic solution in the years to come. Surgical practice of primary tumors is 
considered effective in reducing the risk of metastatic relapse. For instance, the five year 
overall survival of colorectal cancer patients that receive a surgery at early stages of the 
diseases is 95%. An effective surgery is accompanied to an early and accurate diagnosis 
and avails of high-resolution imaging and endoscopy systems. Moreover, surgery is 
becoming less invasive and more selective, to the great benefit of patients in terms of time 
of recovery and quality of life.  
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1. Optimized and targeted therapies - Radiotherapy and chemotherapy based on alkylating 
agents, platinum-based drugs and anti-metabolites (such as analogs of DNA bases) have 
been the first therapeutic strategies still widely used in clinical oncology in association to 
surgery. These strategies are active against rapidly dividing cells, a characteristics share by 
all tumors. However, they can be very toxic, poorly tolerated by patients and often leading 
to secondary tumors (both radiation and anti-cancer drugs are carcinogens themselves). 
Moreover, they can be ineffective, since often cancer can become resistant to most 
conventional therapies. For these reasons, cancer therapy is seeking for more selective and 
personalized approaches, targeting components, which are specifically or abnormally 
present in cancer cells of oncologic patients. In the last decades, the molecular 
characterization of cancer has led to the discovery of components that can be selectively 
targeted by cancer drugs, such as (i) oncogenic proteins responsible for uncontrolled 
signaling of cell cycle and proliferation, (ii) mutated tumor suppression proteins, and (iii) 
cancer-specific surface-associated proteins. A plethora of novel targeted therapies are 
under clinical validations, whose individual components can be categorized in three major 
types: 1) small molecules, specifically selected to block aberrant signaling proteins or 
biological pathways activated in cancer due to the absence of properly functioning tumor 
suppression genes, 2) passive immunotherapy with mAbs able to bind cancer-specific 
surface proteins and capable of killing cancer cells, and 3) active immunotherapy in which 
tumor markers are exploited as antigens and delivered to patients with proper adjuvant 
formulation able to break the immune-tolerance and elicit cytotoxic immune responses.    
Overall, targeted cancer therapies give doctors a better way to tailor cancer treatment, 
especially when a target is present in some but not all tumors of a particular type, as is the 
case for HER-2-positive breast cancers. Ideally, treatments could be personalized based on 
the unique set of molecular targets produced by the patient’s tumor. Targeted cancer 
therapies also hold the promise of being more selective for cancer cells than normal cells, 
thus harming fewer normal cells, reducing side effects, and improving quality of life. 
Nevertheless, targeted therapies have some limitations. Chief among these is the potential 
for cells to develop resistance to them. In some patients who have developed resistance to 
imatinib, for example, a mutation in the BCR-ABL gene has arisen that changes the shape 
of the protein so that it no longer binds this drug as well. In most cases, another targeted 
therapy that could overcome this resistance is not available. It is for this reason that 
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targeted therapies may work best in combination, either with other targeted therapies or 
with more traditional therapies. 
 
Overall, the discovery highly selective tumor-specific markers will enable an early and accurate 
diagnosis and offer new perspective for the development of novel targeted drugs, among which 
mAbs are emerging therapeutic opportunities.  
 
1.2 Tumor Markers 
Ideal tumor markers are molecules able to accurately distinguish a cancerous state, discriminate 
different cancer types and become targets for selective therapy capable of specifically recognizing 
and destroying tumor cells without damaging the surrounding normal tissues. Tumor marker can 
be categorized in four major classes based on their clinical use.  
1- Diagnostic markers are used for the early detection of cancer. Moreover, their aberrant 
expression level can be used to monitor cancer progression in patients subjected to a given 
therapeutic regimen. For instance, a marker decrease or return to a normal level could be 
associated to a relapse-free state or indicate that cancer is responding to therapy. Of 
particular relevance are markers released in biological fluids of cancer patients and can be 
detected with non-invasive immunological assays.  
2- Prognostics markers are indicative of the severity and likely outcome of the disease at time 
of diagnosis. The prediction of poor or favorable prognosis helps the clinician in the 
decision making process and improve the patients’ management.  
3- Predictive markers are helpful to predict the patients’ response to drug therapies and allow 
clinicians to select the most appropriate therapeutic regimen while avoiding ineffective 
treatments. 
4- Therapeutic markers are molecules, frequently receptors, oncogenes or key components of 
molecular pathways that can be used to develop tumor-specific ligands able to block their 
action, such as small molecules and mAbs. 
 
Table 2 reports the protein markers currently used in clinic and their application 
(Http://cancer.gov/cancertopics/factsheet/detection/tumor-markers) 
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Table 2. Clinical cancer markers currently in use in clinic 
TUMOR MARKER CANCER TYPES TISSUE APPLICATION 
ALK gene Lung cancer Tumor 
To help determine 
treatment and prognosis 
AFP(alpha-fetoprotein) 
Liver cancer and germ cell 
tumors  
Blood 
Diagnostic and 
prognostic 
B2M (Beta-2-microglobulin) 
Multiple myeloma, chronic 
lymphocytic leukemia, and some 
lymphomas 
Blood and 
urine 
Diagnostic and 
prognostic 
Beta-Hcg (Beta-human 
chorionic gonadotropin)  
Choriocarcinoma and testicular 
cancer 
Blood and 
urine 
Diagnostic, prognostic 
and predictive 
BCR-ABL Chronic myeloid leukemia  
Blood and/or 
bone marrow 
Diagnostic and 
prognostic 
BRAF mutation V600E Melanoma and colon cancer Tumor Therapeutic 
CA15-3/CA27.29 Breast Blood Predictive 
  
CA19-9 
Pancreatic cancer, gallbladder 
cancer, bile duct cancer, and 
gastric cancer 
Blood Predictive 
CA-125 Ovary tumor Blood 
Diagnostic, predictive 
and therapeutic 
Calcitonin Medullary thyroid cancer Blood 
Diagnostic, prognostic 
and predictive 
CEA Colon and breast cancer Blood 
Diagnostic, prognostic 
and predictive 
Chromogranin A (CgA) Neuroendocrine tumors Blood 
Diagnostic, prognostic 
and predictive 
Chromosome 3, 7, 17and 
9p21 
Bladder cancer Urine Prognostic 
Cytokeratin fragments 21-1 Lung cancer Blood Prognostic 
EGFR mutation analysis Non small cells lung cancer Tumor 
Therapeutic and 
prognostic 
Estrogen receptor 
(ER)/progesterone receptor 
(PR) (ER/PR) 
Breast cancer Tumor Therapeutic 
HE4 Ovary tumor Blood Predictive 
HER2/neu 
Breast cancer, gastric cancer, and 
esophageal cancer 
Tumor Therapeutic 
Immunoglobulins 
Multiple myeloma and 
Waldenström macroglobulinemia  
Blood and 
urine 
Diagnostic, prognostic 
and predictive 
KRAS mutations 
Colorectal cancer and non-small 
cell lung cancer 
Tumor 
Therapeutic and 
prognostic 
Nuclear Matrix protein 22 Bladder cancer Blood Prognostic 
Prostate specific antigen 
(PSA) 
Prostate cancer Blood 
Diagnostic, prognostic 
and predictive 
Thyroglobulin Thyroid cancer Tumor Prognostic 
21 Gene signature Breast cancer Tumor Prognostic 
70 Gene signature Breast cancer Tumor Prognostic 
 
Currently, despite the importance of the cancer markers that account for a considerable area of 
oncology research, only a few are recognized as valid and used in the clinic, as they do not have 
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sufficient specificity and sensitivity to distinguish cancer cells and allow an accurate and timely 
diagnosis. For example, the "Carcinoembryonic Antigen" (CEA) and the "Prostate Specific 
Antigen" (PSA) , are proteins detectable in the sera of patients and routinely used in the clinic to 
predict the presence of the tumor or to monitor the patient's response to treatments for colon or 
prostate cancers, respectively. Concerning CEA, this marker has the advantage of being dosed 
accurately and in a reproducible way, with minimal costs, and for these characteristics it has been 
used in the past for the screening of colorectal tumors (2). Subsequent studies have shown that 
CEA is inadequate for this purpose, being expressed in a variety of extra-intestinal tumors , such 
as cancers of the lung , ovary and bladder. Similarly other markers used for the diagnosis of 
tumors of the colon, such as the "Tumor - Associated Glycoprotein -72" (TAG -72 ) , a high 
molecular weight glycoprotein expressed in a variety of tumors , and the " Carbohydrate Antigen " 
CA19 -9 were inadequate diagnostic tools (2,3). Regarding the PSA, this protein is organ specific 
rather than tumor-specific. Although this marker has been of great help to facilitate the detection 
of prostate cancer, it also presents limited specificity as its serological levels may be altered in 
inflammatory conditions, benign prostatic hyperplasia, and trauma. Recent studies have identified 
new molecular forms of PSA , such as free PSA ( fPSA ) and PSA derivatives, which could be 
more appropriate to discriminate prostate cancer from benign neoplastic states (4). Another marker 
sometimes used for screening of women with high risk of ovarian cancer is the "Cancer Antigen 
125" (CA- 125). Even in this case, changes in the levels of serological CA- 125 are not 
sufficiently specific and sensitive for population screening. CA- 125 is mainly used to monitor 
response to cancer treatment and check for recurrence of ovarian cancer (3). In addition to the 
markers mentioned, in the last 30 years, other proteins, hormones and enzymes have been used, 
but their level increases even in benign conditions and during pregnancy.  
Despite thousands of researchers around the world are engaged in the study of cancer, today many 
areas of biology and physiology of tumors are unexplored and there is a pressing need to identify 
new markers suitable for clinical use. 
 
1.3 MAbs and their use in cancer therapy 
Immunotherapy represents the most attractive opportunity for the treatment of cancer and it is 
pushing the clinical research from more than a century. In particular, mAb therapy is emerging as 
a powerful solution for the treatment of cancer. The popularity of mAbs stemmed from the advent 
of hybridoma technology in 1975 and progressed through the development of chimeric, 
humanized, and human antibodies (5). In fact, before mAbs can be used in humans, they are 
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“humanized” by genetic engineering by replacing as much as possible of the animal portion of the 
molecule with human portions to prevent the human immune system from recognizing the mAb as 
“foreign” and destroying it before it has a chance to interact with and inactivate its target. Being 
directed against tumor-specific or tumor-associated antigens, mAbs can selectively eliminate 
tumor cells while maintaining an acceptable toxicity profile. Moreover, an emerging immune-
therapeutic strategy exploits mAbs that target immune cells with the goal of breaking local 
tolerance and stimulating the patient’s anti-tumor immune response.  
 
mAbs can be used as naked molecules or conjugated with cell payloads (radioisotopes, drugs or 
toxins) to direct kill tumor cells or to activate pro-drugs specifically within the tumors. These 
antibody-drug conjugates (ADC) can deliver a toxic load selectively to the tumor site while 
normal tissues are generally spared. ADC are of particular interest in that their therapeutic efficacy 
is stronger than that of naked antibodies. The concept that mAbs could be used as vehicles for the 
selective delivery of cytotoxic agents to tumors has been around almost since the beginning. 
However, until very recently, the idea has eluded successful implementation, probably for three 
reasons: (i) the use of antibodies against targets that were not sufficiently restricted to tumor cells, 
(ii) the use of drugs with insufficient potency or (in the case of bacterial or plant toxins) that were 
immunogenic, and (iii) the linker chemistry used to attach drugs to antibodies was not optimized. 
The most important property of antibodies to be used for the generation of ADC is their specificity 
for cancer cells, and the ability to be efficiently internalized by them so as to deliver the toxic 
compound in the intracellular compartment. In order to minimize toxicity, conjugates are usually 
engineered based on molecules with a short serum half-life (e.g. the use of IgG3 or IgG4 isotypes). 
Concerning the linker chemistry issue, this aspect has so far required an enormous empirical effort 
(6,7). For instance, a linker that is too labile allows a too rapid dissociation of the drug from the 
antibody causing high drug level in the blood and its exposure of normal tissues. Conversely, 
stable linkers require complete proteolytic digestion of the ADC to release the cytotoxic drug as 
the active metabolite (8). Similarly, the choice of drug required a great deal of trial and effort. So 
far, the most successful drugs are microtubule antagonists. 
 
Currently, thirteen antibodies are approved for use in oncology with different therapeutic 
indications (9,10), described below and grouped on the basis of their major mechanism of action 
(http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted). 
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- MAbs blocking specific enzymes and growth factor receptors involved in cancer cell 
proliferation.  
1. Trastuzumab (Herceptin®) is approved to treat certain types of breast cancer as 
well as some types of gastric or gastroesophageal junction adenocarcinoma. The therapy is 
a mAb that binds to the human epidermal growth factor receptor 2 (HER-2). HER-2, a 
receptor with tyrosine kinase activity, is expressed at high levels in approximately 15-20% 
of breast cancers and also some other types of cancer. The mechanism by which 
trastuzumab acts is not completely understood, but one likely possibility is that it prevents 
HER-2 from sending growth-promoting signals (Figure 2). Trastuzumab may have other 
effects as well, such as inducing the immune system to attack cells that express high levels 
of HER-2.  
2. Pertuzumab (Perjeta™) is approved to be used in combination with trastuzumab 
and docetaxel to treat metastatic breast cancer that expresses HER-2 and has not been 
treated with chemotherapy or a HER-2-directed therapy. Pertuzumab is a mAb that binds 
to HER-2 at a region distinct from trastuzumab. This region allows HER-2 to interact with 
other receptors, such as Her3, to send growth-promoting signals. The drug likely prevents 
HER-2 from sending growth signals and induces the immune system to attack HER-2-
expressing cells (Figure 2). 
3. Cetuximab (Erbitux®) is a mAb that is approved to treat some patients with 
squamous cell carcinoma of the head and neck or colorectal cancer. The drug binds to the 
external portion of EGFR, thereby preventing the receptor from being activated by growth 
signals, which may inhibit signal transduction and lead to antiproliferative effects. 
4. Panitumumab (Vectibix®) is approved to treat some patients with metastatic colon 
cancer. This mAb attaches to EGFR and prevents it from sending growth signals. 
Other targeted therapies block the growth of blood vessels to tumors (angiogenesis). To 
grow beyond a certain size, tumors must obtain a blood supply to get the oxygen and 
nutrients needed for continued growth. Treatments that interfere with angiogenesis may 
block tumor growth. 
5. Bevacizumab (Avastin®) is a mAb that is approved for the treatment of 
glioblastoma. The therapy is also approved to treat some patients with non-small cell lung 
cancer, metastatic colorectal cancer, and metastatic kidney cancer. Bevacizumab binds to 
VEGF and prevents it from interacting with receptors on endothelial cells, blocking a step 
that is necessary for the initiation of new blood vessel growth. 
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- MAbs working by helping the immune system to destroy cancer cells. 
6. Rituximab (Rituxan®) is a mAb that is approved to treat certain types of B-cell 
non-Hodgkin lymphoma and, when combined with other drugs, to treat chronic 
lymphocytic leukemia (CLL). The therapy recognizes a molecule called CD20 that is 
found on B cells. When rituximab binds to these cells, it triggers an immune response that 
results in their destruction. Rituximab may also induce apoptosis. 
7. Alemtuzumab (Campath®) is approved to treat patients with B-cell CLL. The 
therapy is a mAb directed against CD52, a protein found on the surface of normal and 
malignant B and T cells and many other cells of the immune system. Binding of 
alemtuzumab to CD52 triggers an immune response that destroys the cells. 
8. Ofatumumab (Arzerra®) is approved for the treatment of some patients with CLL 
that does not respond to treatment with fludarabine and alemtuzumab. This mAb is 
directed against the B-cell CD20 cell surface antigen. 
9. Ipilimumab (Yervoy™) is approved to treat patients with unresectable or metastatic 
melanoma. This mAb is directed against cytotoxic T-lymphocyte-associated antigen-4 
(CTLA-4), which is expressed on the surface of activated T cells as part of a “checkpoint” 
to prevent a runaway immune response. By inhibiting CTLA-4, ipilimumab stimulates the 
immune system to attack melanoma cells. 
 
- MAbs formulated as ADCs able to deliver the toxic drug into the cancer cells  
10.  Tositumomab and 131I-tositumomab (Bexxar®) is approved to treat certain types 
of B-cell non-Hodgkin lymphoma. The therapy is a mixture of mAbs that recognize the 
CD20 molecule. Some of the antibodies in the mixture are linked to a radioactive 
substance called iodine-131. The 131I-tositumomab component delivers radioactive energy 
to CD20-expressing B cells specifically, reducing collateral damage to normal cells. In 
addition, the binding of tositumomab to the CD20-expressing B cells triggers the immune 
system to destroy these cells. 
11. Ibritumomab tiuxetan (Zevalin®) is approved to treat some patients with B-cell 
non-Hodgkin lymphoma. The therapy is a mAb directed against CD20 that is linked to a 
molecule that can bind radioisotopes such as indium-111 or yttrium-90. The radiolabeled 
forms of Zevalin deliver a high dose of radioactivity to cells that express CD20. 
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12. Brentuximab vedotin (Adcetris®) is approved for the treatment of systemic 
anaplastic large cell lymphoma and Hodgkin lymphoma that has not responded to prior 
chemotherapy or autologous stem cell transplantation. This agent consists of a mAb 
directed against a molecule called CD30, which is found on some lymphoma cells, linked 
to a drug called monomethyl auristatin E (MMAE). The antibody part of the agent binds to 
and is internalized by CD30-expressing tumor cells. Once inside the cell, the MMAE is 
released, where it induces cell cycle arrest and apoptosis.  
13. Ado-trastuzumab emtansine (Kadcyla®), is approved for the treatment of Her2-
positive metastatic cancer who have received prior treatment with Herceptin and Taxane 
chemotherapy. It consists in Trastuzumab, directed against HER-2, conjugated to the a 
maytansine derivative DM1 (Figure 2) 
 
 
Figure 2. Specificity of and mechanism of action of therapeutic targeting HER2 and EGFR. The figure 
represents the epitope recognition of Trastuzumab (A), Pertuxumab (B), Cetuximab or Panitumumab (C), 
and the ADC ado-trastuzumab conjugated to DM1 (D). In the Her2 signaling, Her2 phosphorylates the 
Her3 cytoplasmic domain and this activates the phosphatidylinositol-3-phosphate kinase cascade. 
Conversely, Her3 activation by its binding ligans (e.g. can allosterically activate Her2 kinase). The anti-
Her2 antibodies target the physical and functional interaction of Her2 with Her3. Pertuzumab block the 
heterodimerization of Her2 and Her3. In the case of Ado-trastuzumab conjugated to DM1, the cytoxic 
effect is potentiated by the DM1 drug (modified from Mark X, Science 341, 1192, 2013) 
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Despite the encouraging clinical data, available mAbs are still insufficient to cope with the 
complexity of tumor biology and ultimately to provide satisfactory therapeutic interventions. 
Indeed, several mechanisms of resistance are emerging that limit the antibody therapy efficacy, 
including activation of alternative signaling pathways, genetic mutations and expression of 
immune inhibitory molecules. Altogether, these evidences prompt the search and development of 
new molecular targets and mAbs to improve future therapies and tumor patient health care. 
Moreover, the clinical success of antibody therapy is dependent on a thorough comprehension of 
their effects of on tumor cells and their mechanism of action. In this scenario, highly sensitive 
technologies are needed to understand the local physiological conditions present at a cellular 
level, the tumor microenvironment and the regulatory networks that might influence the behavior 
of molecular targets and their response to mAb therapy. Moreover, as with other treatment 
modalities, mAb-based immunotherapy is far from perfect and requires additional study to 
optimize clinical response and overcome therapeutic resistance. 
 
1.3.1 Mechanisms of action of therapeutic mAbs 
The mechanism by which naked therapeutic mAbs exert their anti-tumor effect can be grouped the 
following categories: 1) perturbation of tumor cell signaling, 2) activation of complement 
dependent cytotoxicity (CDC), 3) antibody dependent cellular cytotoxicity (ADCC), 4) induction 
of adaptive immunity (10).  
Perturbation of tumor cell signaling. Antibodies of this class target soluble mediators (e.g 
cytokines) or membrane bound receptors to inhibit their ability to bind their cognate ligands and 
regulate signaling, and can act as agonists or antagonists. For examples, antagonistic antibodies 
target the epidermal growth factor receptor (EGFR), or other growth factors over-expressed in 
cancer, and inhibit their ability to mediate mitogenic signaling (11,12) . Other type of antibodies 
can inhibit immune suppressing receptors, e.g. CTLA-4, or enhance antigen presentation on APCs 
through the activation of receptors such as CD40 (13,14). Antibodies designed for signal 
perturbation frequently belong to the IgG2 and IgG4 subclasses, as they do not activate CDC or 
ADC and have fewer immune related adverse events due to non specific immune activation (15). 
 
Complement Dependent Cytotoxicity (CDC). The human complement is a complex proteolytic 
cascade comprised of over thirty proteins involved in different innate immunity responses, such as 
acting to lysis of foreign cells through the assembly of the membrane attack complex (MAC), 
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stimulate inflammatory processes through anaphylatoxins, and remove opsonized targets (16,17). 
When two or more antibodies bind to a cell, the classical complement pathway is activated 
through the binding of the C1 complex, a serine protease consisting of C1q, C1r and C1s, to the 
antibody’s Fc domains. This activates a proteolytic cascade that leads to the formation of the 
MAC and the release of potent anaphylatoxins and opsonins resulting in cell lysis and 
phagocytosis (16,18). The ability of human IgG to activate CDC varies depending on the isotype. 
IgG3 followed by IgG1 are the most effective isotypes for stimulating the classic complement 
cascade: both isotypes bind to C1q leading to formation of C3b on the surface of antibody-coated 
tumor cells near the site of complement activation. IgG2 antibodies are less efficient in activating 
the complement cascade, whereas IgG4 is unable to do so (19).  
CDC is an important contributor to the anti-tumor activity of many therapeutic antibodies, such as 
Rituximab and Ofatumumab. As already said, Rituximab is a type I chimeric antibody targeting 
CD20 approved for treatment of many B cell malignancies and is a potent activator of CDC. It 
inhibits internalization and shedding of CD20 and shifts CD20 onto lipid rafts, increasing the 
likelihood of complement activation through the assembly of rituximab bound receptors (20). The 
connection of its therapeutic efficacy with CDC activity has been demonstrated in several studies. 
In one of them, using in vivo lymphoma model it was found that loss of C1q abrogated the 
protective effects of rituximab therapy (21). Data from clinical studies showed that 
polymorphisms in the C1qA gene in patients with follicular lymphoma are associated with 
response to rituximab therapy (22). However, some undesired effect of rituximab seems to due to 
its CDC activity. One small clinical study found that, following rituximab therapy, patients had 
high circulating levels of circulating complement components with associated severe toxicity 
(23,24).  
Ofatumumab is another type-I anti-CD20 antibody that binds to a distinct epitope of CD20 and 
induces greater CDC com-pared to rituximab(25). The higher efficacy of Ofatumumab could be 
ascribed to the fact that it binds C1q with greater avidity than rituximab and efficiently kills 
rituximab-resistant large B-cell lymphoma cell lines. Moreover it is able to lyse cell lines 
expressing low levels of CD20, which are not efficiently killed by rituximab (26). Clinical trials 
data showed that ofatumumab has high response rates in patients with refractory chronic 
lymphocytic leukemia (CLL) (27). 
 
Antibody Dependent Cell-Mediated Cytotoxicity (ADCC). ADCC is activated by the interaction of 
the Fc domain with FcγRs on effector immune cells,. The stimulation of immune-receptor 
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tyrosine-based activation motifs and immune-receptor tyrosine-based inhibitory motifs results in 
activating or inhibitory signals through FcγRs, respectively. There are three activating FcγRs: 
FcγRI (CD64), which binds to monomeric IgG and tends to be occupied by plasma IgG, the low-
affinity FcγRIIA (CD32A), and FcγRIIIA (CD16A) which bind IgG aggregates or 
immunocomplexes, and one inhibitory receptor, FcγRIIB (CD32B) (28,29).  
Natural killer (NK) cells, which predominantly express FcγRIIIA, are the main effector cells of 
ADCC, although macrophages and granulocytes cells have been shown to mediate ADCC to a 
lesser extent (28). These effector cells, through the involvement of FcγRs, recognize antibodies 
bound to cancer cell and cause their direct lysis through release of granzymes and perforin which 
culminates in antibody-dependent cell-mediated cytotoxicity (ADCC). Upon crosslinking of 
FcγRIIIa by the immune complex, the immunoreceptor tyrosine-based activation domain is 
phosphorylated by the SRC family tyrosine kinase LYN, thereby inducing the formation of a 
signaling complex (29). This signaling complex results in the activation of phospholipase C, 
which hydrolyzes phosphatidylinositol-3,4-bisphosphate [PtdIns(4,5)P2] into diacylglycerol 
(DAG) and inosititol-1,4,5-triphosphate [Ins(1,4,5)P3], thereby inducing a number of signaling 
events including calcium influx from the endoplasmic reticulum and the opening of calcium-
release-activated calcium channels (29,30). The increased intracellular calcium induces the serine/ 
threonine phosphatase calcineurin to dephosphorylate the nuclear factor of activated T cells 
(NFAT). Dephosphorylation of cytoplasmic NFAT exposes a nuclear localization sequence that 
causes translocation of this transcription factor to the nucleus where it induces the expression of a 
number of genes involved in the ADCC pathway (29,31). These effects are dependent on a 
number of factors including the density of the antigen on the cell surface and the isotype of the 
antibody. Of the drugable human IgG isotypes, IgG1 is reported to be the best at inducing effector 
function and is selected as the isotype for the antibody in indications such as the treatment of 
cancer where cell killing may be part of the mechanism of action. In cases where cell killing is not 
wanted, IgG2 or IgG4 are the isotypes of choice since they have limited ability to activate effector 
function, 
 
Among others, two common mAbs with ADCC activity are trastuzumab and rituximab, which 
require functional activating FcγRs to exert their activity (32). Recent studies highlighted two 
determinants that could influence the clinical efficacy of therapeutic antibodies with ADCC 
activity. The first determinant is the balance between expression of activating and inhibitory 
FcγRs. In support of this notion, it has been shown that animals lacking expression of FcγRIIB 
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displayed a greater anti-tumor response when treated with therapeutic antibodies (32). The second 
determinant is the level of macrophages which can act as an effector for ADCC. High levels of 
macrophages are normally considered as prognostic factor for poor survival. However, two 
independent clinical studies have shown that follicular lymphoma patients with high levels of 
tumor associated macrophages have an improved response to rituximab (33), which might be 
ascribed to an increase in ADCC.  
 
Induction of Adaptive Immunity. Numerous pre-clinical studies support the notion that tumor 
targeted antibodies can elicit adaptive immune responses, and a growing body of clinical evidence 
suggests that this mechanism may contribute to the clinical efficacy of antibodies. The mechanism 
by which this can happen is multiple and involves CDC, ADCC, or antibody dependent cell-
mediated phagocytosis (ADCP). Tumor cell fragments and tumor antigens released during these 
processes can be taken up by professional APCs, such as DCs, to initiate tumor directed adaptive 
immunity. In addition, antibodies can trigger adaptive immunity by acting as an opsonin and 
triggering Fc dependent phagocytosis of tumor cells by APCs. Tumor antigens are processed by 
DCs through the endocytic pathway and presented on MHC II to prime CD4+ T cells. In addition, 
DCs are capable of presenting engulfed tumor antigens on MHC I molecules and elicit tumor-
specific CD8+ cytotoxic T-cells (CTLs). Upon activation, CTLs can directly kill tumor cells that 
present the cognate peptide on MHC I, or further differentiate into tumor specific memory T cells 
(34).  
Preclinical studies showed that DCs loaded with ovarian and melanoma cells coated with 
antibodies were able to elicit tumor specific CTLs able to kill primary ovarian and melanoma cells 
(35). A recent study showed that colon cancer cell lines coated with cetuximab, were able to 
induce tumor specific CTLs from autologous human DCs (36). Overall, the elicitation of adaptive 
immunity could potentially sustain anti-tumor immune responses in patients.  
 
Immunotherapy approaches to activate the immune systems. 
A number of molecular engineering approaches are undertaken to enhance the antibody capacity 
to activate immune effector mechanisms and/or to overcome the suppressive tumor 
microenvironment. One approach is based on the generation of non-fucosylated antibodies, In fact, 
it has been shown that highly fucosylated Fc significantly impair immune activation. Advanced 
clinical studies with non-fucosylated antibodies are currently ongoing with promising results (37). 
Another approach is that of bispecific tri-functional antibodies (so called triomabs) which have 
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two distinct Fab regions capable of binding two distinct epitomes, which can simultaneously bind 
tumor cells and immune cells while maintaining the capacity to mediate Fc dependent effector 
functions. To this class belongs Catumaxomab, a tri-omab that targets the tumor antigen EpCAM 
and the T-cell stimulatory receptor CD3, which allows for direct stimulation of CTLs in the tumor 
microenvironment (38). However, the complexity and the very high cost associated with this 
technology are preventing its widespread development. 
Finally, a promising cancer immunotherapy strategy is to target the effector cells that largely 
contribute to the immune suppressive tumor microenvironment. As already said, Ipilimumab 
inhibits the potent immune suppressor molecule CTLA- 4 that is expressed by Tregs and 
consequently, the capacity of Tregs to inhibit the anti-tumor immune response is diminished, 
resulting in increased levels of CTLs, CD4+ T cells, and APCs (14,39). Following the success of 
ipilimumab, other mAbs that are emerging from clinical studies are those that antagonize the 
interaction of programmed death–1 (PD-1), another negative regulator of T cells with its ligands 
PD-L1 and PD-L2 (40). The PD-1/PD-L1 axis serves as another front-line mechanism of immune 
suppression in tumor, whose role is to prevent the unrestrained activation of T cells that have been 
previously activated and probably to contribute to maintain peripheral tolerance. During antigen 
presentation by dendritic cells, PD1 can act as a checkpoint inhibitor which can sent a negative 
signal by its binding to either PD-L1 or the closely related (and dendritic cell–specific) negative 
regulatory ligand PD-L2.. The addition of mAbs to either PD-1 or PD-L1 blocks their interaction, 
thereby rescuing T cell cytotoxic activity. Often, this results in rapid and substantial tumor 
shrinkage coupled with long-term responses (40). Two antibodies against PD-1 (nivolumab and 
lambrolizumab) and one to PD-L1 (MPDL3280A) are the most advanced in the clinic studies, and 
show less serious adverse effect than Ipilimumab. 
Antibodies that block immune checkpoints and immune suppression in the tumor bed have so far 
produced long-term, durable patient responses rarely seen with other therapeutics and, as such, 
their development is expected in increase in the coming years.  
 
Overall, in the last decade mAb therapy has revolutionized the treatment of cancer and it will 
continue to dominate in the years to come, in conjunction with other treatment chemotherapy. 
Presently, the best hope to maximize the efficacy of antibody therapy is represented by rational 
combinations of mAbs targeting tumor-specific antigens, either as naked or as ADCs, with 
antibodies targeting the immunosuppressive tumor microenvironment. The use of these antibody 
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combinations is expected to significantly lower the amount of cytotoxic chemotherapy that is still 
the main pillar of most systemic oncology treatments.  
 
1.4 Externautics approach for tumor marker discovery 
This PhD project has been conducted at Externautics, a Company located in Siena at the incubator 
Toscana Life Sciences (TLS). Externautics is a research company whose objectives consist in the 
discovery and pre-clinical validation of novel cancer markers and therapeutic targets, and the 
generation of mAbs for the diagnosis and treatment of prevalent human cancers. Briefly, the 
Externautics’ approach for marker discovery and development of mAbs exploits the availability 
of an in-house generated collection of about 2600 murine polyclonal antibodies (pAbs) directed 
against secreted and membrane-associated human recombinant proteins only marginally 
characterized in the scientific literature (41). The library of pAbs is used screen Tissue 
Microarrays (TMAs) carrying clinical samples from pedigreed patients affected by breast, colon, 
lung, prostate and ovary tumors, generated at the European Oncology Institute (Milan, Italy). The 
concomitant presence on the TMAs of both cancerous and normal tissues from the same patients 
allows to discriminate the pAbs able to selectively cancer samples, thus providing a first-hand 
indication that their target proteins are over-expressed in tumor. After their initial discovery, the 
novel potential cancer markers are extensively validated using molecular and cellular biology 
experiments aimed at identifying whether they could be exploited as diagnostic markers or 
therapeutic targets, including analysis of antibody specificity, gene expression profiling in tumor 
cell lines, marker cell localization and biological characterization. Finally, murine mAbs (mAbs) 
are generated against the markers by immunizing animals with the recombinant protein and/or 
selected domain of the protein. Afterwards, the mAbs are further characterized so as to select the 
most promising candidates to be brought to the pre-industrial development phase, ready to enter 
the clinical development phase. 
The strategy workflow is expected to generate tumor markers and mAbs with potential 
applications in the cancer diagnostics, small molecules and antibody therapeutics, and vaccine 
fields. 
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Figure 3 – Experimental approach used by Externautics for tumor marker discovery and characterization.  
 
The screening of the pAb collection on TMAs carrying clinical specimens from 5 patients per 
each tumor has currently allowed the identification of 89 novel tumor-associated proteins 
differentially expressed in one or more tumors. These proteins are distributed in all the five tested 
tumors with approximately one fifth selectively over-expressed in only one tumor, one third in 
two tumors and the remaining part in three or four tumor types (Figure 4A). Most of these proteins 
show several annotated variants, resulting from alternative splicing events, predicted to be found 
in different cellular compartments. Bioinformatic analysis predicts that approximately 30% of the 
89 proteins have at least a variant associated to the plasma membrane, 50% have a secreted 
isoform and the remaining proteins are associated to the internal cell membranes, such as those 
belonging to the Golgi apparatus and mitochondrion (Figure 4B). 
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Figure 4 – Representation of the 89 novel markers discovered by Externautics. A) Distribution of IHC 
positivity of the 89 markers in the five tumor types. B) Predicted cell localization of the markers. 
 
The 89 proteins are currently under characterization. An expanded IHC analysis so far conducted 
for 27 proteins on 50 patients per tumor showed that 19 of them are over-expressed in one or 
more cancers with frequencies ranging from 20% to 96% (9 pending patents: 
PCT/EP2010/000503, PCT/EP2010/000502; PCT/EP2010/066147, PCT/EP2010/066144, 
PCT/EP2010/066146, PCT/EP2010/066154, PCT/EP2010/066134, EP10161559.9). 
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1.5 EXN11 and EXN6, two novel tumor-associated proteins 
The present study focuses on EXN11 and EXN6, two novel markers identified in the primary 
TMA screening. EXN6 is a single-pass type II membrane protein with a carbohydrate-binding 
domain. Apart from sequence annotation, EXN6 is almost unknown and no data are available on 
its expression, biological function and association to cancer. As far EXN11 is concerned, this 
protein shows homology the angiopoietin-like (ANGPTL) proteins, a family of secreted proteins 
with structural similarity to members of the angiopoietin (ANG) family, with which they share a 
coiled-coil domain at the N-terminus and a fibrinogen-like domain at the C-terminus. Most 
members of this family are emerging as central players of different cell processes and human 
diseases. Several ANGPTL proteins potently modulate angiogenesis (42-45), though for some of 
them the effect remains controversial. Similarly, their involvement in tumor and tumor-
angiogenesis has been only partially elucidated. ANGPTLs are also involved in other processes 
independently from angiogenesis, such as augmentation of energy expenditure, induction of 
inflammation, and metabolism (44-47), as well as in associated diseases, such as metabolic and 
cardiovascular diseases (48). Concerning the EXN11, its role in angiogenesis and expression in 
human cancer has not been reported yet. 
 
2. AIM OF THE PROJECT 
Scope of the experimental work of this PhD thesis was twofold. The first objective of the project 
was the confirmation and characterization of EXN6 and EXN11 as novel tumor-associated 
proteins that could be exploited as diagnostic, prognostic, predictive or therapeutic biomarkers. 
The second objective was to develop specific mAbs able to specifically detect the markers and to 
interfere with tumor-related processes in vitro and/or in vivo.  
1) Marker confirmation and characterization. The activity consisted in confirming the positivity 
of the cancer-reactive antibodies towards EXN11 and EXN6 in an expanded number of patients, 
using TMA representing tissues from 50 patients per each tumor. This confirmatory analysis 
allows to obtain a preliminary statistical analysis on the frequency with which these proteins are 
over-expressed in the tumors in which they were originally discovered. Afterwards, a marker 
characterization study was undertaken, aimed at defining their most likely use of EXN6 and 
EXN11 as diagnostic and/or therapeutic tools. It consisted in different molecular and cell biology 
analyses that allow to assess: i) the marker expression in human cell lines, either endogenous or in 
response to specific environmental stimuli; ii) the marker localization on commercially available 
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tumor cell lines; iii) the marker biological role, by investigating the perturbation of major cell 
processes relevant for tumor development caused by the alteration of marker expression.  
3) Generation and validation of mAbs. The activity intended to develop marker-specific mAbs, 
with priority for the surface-associated protein EXN6. It consisted in generating panel of EXN6-
specific mAbs and confirming the mAb ability to detect the target protein in cancer cells using 
different immunoassays, such as Western blot (WB), flow cytometry, confocal microscopy and 
immuno-histochemistry. The expected achievement was the availability of mAbs able to detect 
EXN6 on the surface of cancer cells and, possibly, to interfere with cellular processes relevant for 
cancer growth.  
 
3. RESULTS 
The Results section separately describes the major scientific achievements related to EXN6 and 
EXN11.  
 
3.1 EXN6  
3.1.1Confirmation of EXN6 detection in human cancers  
The screening of the antibody collection on TMA carrying tumor and matched normal samples of 
5 patients per each tumor provided the first experimental evidence that EXN6 is over-expressed in 
breast, lung, colon and ovary tumors. We then confirm the altered expression of EXN6 in larger 
set of samples. To this regard, tumor-specific TMA were generated at IEO carrying clinical 
specimens of breast, colon, ovary and lung cancer (representing 50 patients/tumor) and analyzed 
with the anti-EXN6 pAb. EXN6 was mainly detected in breast (40% positivity) and ovary cancer 
samples (35%). In colon and lung cancer specimen samples it was detected with lower frequency 
(less than 10%, respectively). In these cancers the immuno-histochemical staining mainly 
accumulated at the plasma membrane, leading us to hypothesize that the protein is surface exposed 
(Figure 5).  
 
We then investigated the presence of EXN6 in fresh bioptic specimens of breast cancer by WB. 
Since surgical biopsies are very inhomogeneous and contain epithelium, stroma, and connective 
tissues in variable amount, this analysis does not allow a marker quantitative measurement, but it 
was meant to assess the presence of EXN6 species in cancer, compared to normal samples. Total 
protein extracts were prepared from four biopsies of breast cancer and matched adjacent normal 
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samples, loaded on PAGE-SDS (25 g/lane) and subjected to immunoblot. As shown in Figure 5, 
EXN6 bands (ranging from 55 to 65 kDa) were detected in 3 of the 4 samples, which were absent 
or only marginally visible in normal samples.  
 
 
Figure 5. EXN6 detection in clinical sample specimen by IHC. A) IHC images of positive cancer 
specimens and corresponding normal samples stained with the anti-EXN6 pAb. B) Graph reporting the 
EXN6 detection frequency in clinical specimens from 50 patients/cancer. C)WB analysis of cancer (K) and 
normal (N) breast specimens stained with the anti-EXN6 pAb. Actin was used as sample normalization 
control.  
 
3.1.2. The IHC-reactive anti-EXN6 polyclonal antibody specifically recognizes its target 
protein  
The first experimental step necessary to start EXN6 validation and characterization was to assure 
the specificity of the anti-EXN6 pAb showing reactivity on cancer tissues. This was done by 
analyzing its ability to recognize EXN6 expressed in mammalian cells by  WB and confocal 
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microscopy. The EX66 coding sequence was cloned in vector pcDNA3.1D and the resulting 
plasmid was used to transiently transfect HeLa and/or Hek293T human cell lines. After 24 hours, 
total cell extracts were prepared with and without DTT, separated by SDS-PAGE (25 
micrograms/lane, corresponding to approximately 1x10
5
 cells) and subjected to immunoblot with 
the anti-EXN6 pAb. As controls, total extracts of EXN6-transfected cells were run in parallel. 
Under reducing condition the anti-EXN6 pAb was able to detect a EXN6 band (approximately 50 
kDa) over-expressed by HeLa cells upon transfection. When  WB was conducted under not 
reducing condition, other more intense high molecular weight bands ranging from 90 to 200 kDa 
were detected, likely corresponding to EXN6 dimers and multimers (Figure 6A). 
For confocal microscopy analysis, EXN6 transfected cells were fixed with para-formaldehyde and 
incubated with the anti-EXN6 pAb, before or after treatment with BRJ96, a detergent used to 
permeabilize the plasma membrane. The anti-EXN6 pAb was able to bind EXN6 transfected cells 
without cell permeabilization (Figure 6B) indicating that, in agreement with its prediction, EXN6 
is surface exposed.  
 
Figure 6 –Specificity of the IHC reactive anti-EXN6 polyclonal antibody. Cells were transfected with a 
EXN6-coding plasmid and the empty vector (mock) and subjected to WB (A) and confocal microscopy 
(B). For WB, total extracts from EXN6 and Mock transfected HeLa cells were prepared with or without 
DTT and used for immunoblot with the anti-EXN6 pAb. The EXN6 monomer and multimer bands are 
marked by arrow and bracket, respectively. For confocal microscopy, trasnfected HEK293T cells were 
fixed, incubated with the anti-EXN6 pAb, followed by incubation with an Alexa 488-conjugated secondary 
antibody. DAPI was used to visualize nuclei.  
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3.1.3 EXN6 is endogenously expressed and surface exposed in breast and ovary cancer cell 
lines 
Confocal microscopy analysis of EXN6 transfected cells confirmed that EXN6 is surface exposed. 
We then investigated EXN6 endogenous expression and localization in cell lines derived from 
breast, ovary and colon cancer cell lines by flow cytometry, using a surface staining setting. 
Among 15 cell lines globally analyzed, the breast cell lines SKBr3, MCF7 and T47D and the 
ovary cell line Ovcar 3 showed FACS positivity (Figure 7A). WB analysis under not reducing 
condition confirmed the presence of EXN6 in these cells (Figure 7B). Moreover, the specificity of 
the EXN6 detected band was confirmed by gene silencing. SKBr3 cells transfected with EXN6 
specific siRNAs o with an irrelevant siRNA (scrambled siRNA) and at 72 hours later EXN6 loss 
of expression was assesses by WB. As shown in Figure 7B, treatment with EXN6 siRNA resulted 
in the reduction of a band of approximately 90 kDa band, likely corresponding to EXN6 dimer. 
EXN6 transcription was significantly reduced at 48h after siRNA treatment, as judged by q-RT-
PCR (not shown). 
Overall, the results confirmed that EXN6 is endogenously expressed in a subset of ovary and 
breast cancer cells, in which it is surface exposed. This evidence suggests that EXN6 is a potential 
drug target in breast and ovary cancers.  
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Figure 7. EXN6 expression and localization in cancer cell lines. A) FACS analysis. The table reports the 
panel of cell lines tested by surface staining using an anti-EXN6 pAb. The four FACS positive cell lines are 
represented in the graphs (Bleu, EXN6-pAb; red,unrelated negative antibody control). B) WB analysis of 
SKBR3. Cells were treated with EXN6-specific or scrambled siRNAs and 72 hours later total extracts were 
prepared with/without DTT for immunoblot, probed with the anti-EXN6 pAb. A major band of 
approximately 90 kDa was detected in cell total extracts, only under not reducing conditions. This band 
showed a weaker intensity in EXN6 silenced cells.  
 
3.1.4. EXN6 is involved in cell proliferation and invasiveness 
Ideal therapeutic targets are key player in signaling pathways frequently activated or altered in 
cancer. This type of proteins enables the generation of drugs able to inhibit their expression and 
function, ultimately leading to the arrest of proliferation, the induction of apoptosis, or alteration 
of cell motility properties. To obtain a preliminary indication of EXN6 relevance in tumor 
development we investigated the phenotypic effect of EXN6 knock-down in the viability, 
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proliferation and migration of breast cell lines. In these experiments, EXN6 silencing was verified 
by q-RT-PCR (not shown). MCF7 cells transfected with EXN6 siRNA or scramble siRNA were 
incubate for 72 either without FBS, for viability analysis, or in the presence of 2,5% FBS, with 
and without 10 ng/ml of EGF, to estimate proliferation. Cell viability and proliferation was 
assessed by the MTT assay, a colorimetric assay that allows to monitor the enzymatic conversion 
of a tetrazolium salt into a purple-colored formazan product in viable cells, by spectrophotometric 
measurement of the adsorbance at 570 nm. As shown in Figure 8A, EXN6 silencing caused a 2-
fold decrease in cell viability and cell proliferation.   
Cell migration / invasiveness was assessed in the Boyden-Matrigel-Assay. This assay employs a 
trans-well chamber in which the upper and lower compartments are separated by a microporous 
membrane. Cells are seeded on the upper compartment and are stimulated to migrate the lower 
compartment under a chemo-attractant stimulus, crossing the porous membrane. When used to 
measure invasiveness, cells must degrade a 3D extracellular matrix (Matrigel) before crossing the 
membrane. After 16h, the number of cells that have migrated to the lower side of the membrane is 
counted. In this assay, MCF7 and SKBR3 cells treated with EXN6-specific siRNAs for 72 hour 
showed a significant decrease of the invasive phenotype, as compared to control cells (Figure 8B). 
The effect was more pronounced in MCF7 (5 fold) than in SKBR3 cells (2 fold). 
 
 
Figure 8– EXN6 is involved in cell proliferation and invasiveness. MCF7 and/or SK-BR-3 cells were 
transfected with EXN6-specific or scrambled siRNA. After 72 hours cells cell viability/proliferation and 
invasiveness was assessed. A) MTT assay. MCF7 cells were exposed to 2.5% FBS, 2.5% FBS+10 ng/ml 
EGF or serum-starved and cell viability/proliferation was measured by the MTT and optical absorbance 
reading. B) Boyden assay. MCF7 and SK-BR-3 were seeded on the upper chamber of a Matrigel-coated 
96-well plates and the number of migrated cells was evaluated after Diff-Quick staining by counting cells 
in six randomly chosen fields. Images below the graphs show the visual counting.  
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3.1.5. Anti-EXN6 mAbs specifically recognize the protein on the surface of breast and ovary 
cancer cells. 
To achieve the proof of concept that EXN6 could be a promising target for mAb therapy, mAbs 
were generated towards recombinant EXN6 using the standard hybridoma technology based on 
the fusion of splenocytes from immunized BALB/c mice with Ag8 myeloma cells (mAb 
production carried out at The Fourth Military University, X’ian, China). After screening by 
ELISA on the recombinant proteins, approximately 20 EXN6-specific mAbs were obtained. 
Afterwards, these mAbs were further screened by WB and FACS on EXN6 transfected 
HeLa/Hek293T cells. In total, five anti-EXN6 mAbs (labelled from 1 to 5) specifically recognized 
EXN6 transfected cells both by WB and FACS (Figure 9A). The five EXN6 mAbs were also 
tested for their ability to detect EXN6 on the surface of breast and ovary cancer cell lines (see 
Figure 7). As shown in Figure 9B, the five mAbs were able to bind the surface of MCF7, T47D, 
SKBr3 and Ovcar3 cell line (Figure 9B). The mAb specificity was confirmed in the EXN6-
positive cells by treating them with different concentration of EXN6 siRNA (ranging from 10 to 
50nM) and monitoring the disappearance of surface binding. EXN6-siRNA treated cells showed a 
significant loss of surface staining, as opposed to cells treated with a scrambled siRNA (see 
exemplary data for anti-EXN6 mAb1 and mAb2 in SKBR3, Figure 9C).  WB analysis on EXN6 
silenced cells further confirmed the mAb specificity (data not shown).  
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Figure 9 – The anti- EXN6 mAbs bind the surface of breast and ovary cell lines. A) FACS 
analysis of EXN6 transfected HEK293T cells with the five anti-EXN6 mAbs (red peak, EXN6 
mAbs, Blue peak, irrelevant isotype control); B) FACS analysis on the EXN6-positive breast and 
ovary cell lines (blue peak, EXN6 mAbs; red peak irrelevant isotype control). C) FACS analysis in 
EXN6 knocked down SKBR3 cells. Cells were transiently transfected with different 
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concentrations of EXN6-specific sirRNA and 72 hours later the residual mAb surface binding was 
measured by flow cytometry as compared to cells treated with an irrelevant siRNA. 
 
3.1.6 Two anti-EXN6 mAbs are efficiently internalized by breast and ovary cancer cells  
Antibody-drug conjugates (ADC) are powerful tools to increase the anti-tumor activity of naked 
antibodies. As already said, the most important property of antibodies suitable for ADC 
development is the ability to be internalized by cancer cells shortly after their surface binding on 
cancer cells, so as to efficiently drive their drug-conjugates into the cells. To assess whether the 
anti-EXN6 mAbs have this important property, internalization experiments have been carried out 
by FACS and confocal microscopy, in breast and ovary EXN6-positive cell lines. Cells were 
incubated for 30’on ice with the five anti-EXN6 mAbs (10g/ml) to allow surface binding, 
subsequently washed to remove the excess of unbound mAbs and then shifted to 37°C for up to 2 
hours to permit the internalization process to occur. As negative control, cells were also incubated 
with a mAb toward CD81, a multipass plasma membrane protein that is not internalized. As 
controls, samples were kept on ice and analyzed in parallel. For FACS analysis, cells were then 
incubated with a fluorescently-labeled secondary antibody, and the disappearance of the anti-
EXN6 mAbs from the cell surface was monitored as function of time. Two of the 5 anti-EXN6 
mAbs (mAb1 and 3) quickly disappeared from the cell surface upon temperature shift (after 30’ 
approximately 50% of surface bound antibodies disappeared from the cell surface) (Figure 10A). 
Conversely, the other 3 mAbs remained associated on the cell surface under the observation 
period (mAb2 example, in Figure 10A). To confirm that the loss of mAb surface binding visible 
upon temperature shift was effectively due the mAb internalization, confocal microscopy was also 
carried out to monitor the formation of intracellular immuno-complexes. In this experiment, after 
1h incubation at 37°C, cells were methanol-permeabilized and incubated with a fluorescently 
labeled secondary antibody. As shown in Figure 10B, upon temperature shift the surface bound 
anti-EXN6 mAb 1 and mAb3 were not detectable on the plasma membrane and accumulated in 
the intracellular milieu, visible as fluorescent spots, confirming that they were efficiently 
internalized (mAb3 example, Figure 10B).  
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Figure 10 – Two anti-EXN6 mAbs are efficiently internalized by tumor cells. Cells were incubated for 
30’ on ice with the EXN6 mAbs, Afterwards, cells were washed and shifted to 37°C for up to 2h. For 
FACS analysis (A), cells were incubated at different time point with an Alexa488-conjugated secondary 
antibody and the residual mAb surface binding was assessed. For confocal microscopy (B), cells were fixed 
and permeabilized before (upper panels) and after incubation at 37°C (lower panels) and the formation of 
intracellular immune-complexes was detected by incubating cells with the secondary antibody. DAPI was 
used to visualize nuclei.  
 
3.1.7 The two anti-EXN6 mAbs promote cell killing in an indirect ADC assay.  
To further confirm that the anti-EXN6 mAbs 1 and 3 could be efficient as ADC, an indirect 
killing assay was used which allows to assess the ability of mAbs to bring a toxin-conjugated 
secondary antibody in the endosomic pathway and release the cytotoxic toxin within the cells. 
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T47D cells were incubated for 30’ on ice with different concentration of mAbs 1 and 3 (from 1 to 
40 g/ml) to allow surface binding and subsequently incubated for 72h at 37°C in the presence of 
a secondary antibody linked to saporin (Fab-ZAP system), a ribosome inactivating toxin, and cell 
killing was measured with the MTT assay and adsorbance reading, as compared to treated with an 
irrelevant mAb. As shown in Figure 11, both anti-EXN6 mAbs were able to promote cell killing 
(up to 40% ).  
Overall, the results indicate that these two anti-EXN6 mAbs hold promise as candidates for ADC 
development. 
 
Figure 11. The anti-EXN6 mAbs promote FabZAP-based killing of cancer cells. T47D cells were 
incubated 30’ on ice with different concentration of mAbs 1 and 3 (from 1 to 40 g/ml) or with an 
irrelevant mAb, then shifted at 37°C and added with a secondary antibody linked to saporin (Fab-ZAP 
system). Cell viability was estimated by the MTT assay. The percentage of cell killing was determined by 
detracting the Adsorbance value of mAb-treated cells from that of control samples, expressed as 
percentage.  
 
3.1.8 The anti-EXN6 mAb1 shows ADCC activity  
As described in the Introduction, ADCC mechanism of action is triggered by antibodies that bind 
their target antigens on the cell surface and, with their Fc effector portion, also bind to FcγRIIIa 
receptors on the cell surface of effector cells, predominantly NK, generating multiple cross-linking 
of the two cell types and ultimately leading to the killing of target cells (49).  
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We assessed the ADCC activity of the anti-EXN6 mAbs using an ADCC-reporter assay. This 
method detects the Fc effector function of mAbs by measuring the activation of the nuclear factor 
of activated T-cells (NFAT) signaling pathway in Jurkat cells that have been engineered to stably 
express the FcγRIIIa receptor (V158 high affinity variant) and a NFAT response element driving 
expression of firefly luciferase. ADCC activity is quantified with luminescence readout through 
the luciferase produced as a result of NFAT pathway activation. This assay has important 
advantages over conventional ADCC systems, in that it is a non radioactive method, it does not 
employ human peripheral blood mononuclear cells (PBMCs) from healthy donors as source of 
NK, while offering accuracy, sensibility and reproducibility of the measurement at the same time.  
In our study, three anti-EXN6 mAbs were incubated at concentrations (ranging from 0 to 20 
g/ml) with T47D target cells (T) and the engineered effector Jurkat cells (E) (E:T ratio: 3). After 
6 hours, the amount of luciferase was determined. Jurkat cells incubated with mAb1 showed an 
increase in the amount of luciferase (about 3 fold) whereas the other antibodies did not stimulated 
its production (Figure 12). 
 
 
 
Figure 12 –An anti-EXN6 mAb with ADCC activity. mAb1, mAb2 and mAb3 were incubated at 
different concentrations with T47D and engineered effector Jurkat cells at an E:T ratio of 3:1 
(75,000 and 25,000 cells/well, respectively). After 6 hours the amount of luciferase produced by 
NFAT activation was quantified by luminescence reading, as compared to untreated cells. RLU: 
Relative Luminescence Unit.  
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3.1.9. The anti-EXN6 mAbs show marginal reactivity on normal human tissues. 
An important aspect in the development of mAbs with therapeutic potential is to assess the 
reactivity with normal human tissues. Indeed, very frequently cancer markers are expressed at 
endogenously level at different site. Alternatively, the mAb coud cross-react with other human 
proteins. To address this aspect we analyzed the immune-reactivity of the anti-EXN6 mAbs on 
the 33 normal human tissues requested by the Food and Drug administration to assess the mAb 
specificity. 
The anti EXN6 mAb 1 and mAb3 were tested on commercially available tissue microarray 
carrying the 33 FDA normal human tissues (MNO961, Pantomics) by IHC, using the same 
staining protocol and mAb concentration used to stain cancer tissue TMA. As shown in Table 2, 
the two antibodies only gave weak cytoplasmic staining pancreatic Langherans cells and they 
were almost negative in all the other tissues. This indicates that these antibodies to not have 
relevant surface associated off-targets in normal tissues and have in general limited reactivity. 
 
Table 2. IHC reactivity of anti-EXN6 mAbs in normal human tissues 
Anatomic site mAb1-mAb3 staining  Anatomic site mAb1-mAb-3 staining 
Adrenal gland negative  Ovary negative 
Bladder, urinary negative 
 
Pancreas 
cytoplasmic staining in 
Langherans cells 
Bone, bone marrow negative  Parathyroid negative 
Eye ND  Pituitary gland negative 
Breast negative  Placenta negative 
Brain, cerebellum negative  Prostate negative 
Brain, cerebral cortex negative  Skin NV 
Fallopian tube negative  Spinal cord negative 
Esophagus negative  Spleen negative 
Stomach negative  Skeletal muscle negative 
Intestine, small 
intestine 
negative 
 
Testis negative 
Intestine, colon negative  Thymus negative 
Intestine, rectum negative  Thyroid negative 
Heart negative  Tonsil negative 
Kidney  negative  Ureter negative 
Liver negative  Uterus, cervix negative 
Lung negative  Uterus, endometrium negative 
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3.2. EXN11 
3.2.1Confirmation of EXN11 detection in human cancers  
The primary IHC screening showed that the EXN11 is expressed in colon cancer (3/5 patients), 
where it showed a significant expression, and it was also detected breast (1/5) and ovary (1/5) 
cancers with lower expression level. We then confirmed EXN11 expression in 30 primary colon 
cancer specimens and 20 samples of liver metastasis from colon cancer. Concerning primary colon 
cancer, EXN11 was detected in 40% of the samples, with concomitant negligible staining in the 
corresponding normal tissues (Figure 13A). In agreement with the fact that EXN11 is a secreted 
protein the immune-histochemical staining was generally moderate and in some cases extended to 
the cell secretion products, as usually observed with antibodies targeting released products. 
Concerning the colon metastasis specimens, it was detected in over-expressed in 50% of the cases 
as compared to normal hepatocytes surrounding the cancerous lesions. In some cases, the IHC 
staining accumulated in the intra-hepatic biliary ducts (Fig 13C). 
 
To confirm the presence of EXN11 in cancer samples, total protein extracts prepared from cryo-
preserved biopsies of colon cancer (4 patients) and ovary cancer (3 patients) were analyzed by  
WB. Surgical resections from normal controls were run in parallel, including 4 colon samples 
from the same patients and 2 ovary samples from different donors. As shown in Figure 13B, a 
band of the expected molecular weight (approximately 45 kDa) was clearly detected in the 4 colon 
and in one ovary cancers samples. In normal samples, the same band was either absent or had a 
weaker intensity. 
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Figure 13. Detection of EXN11 in cancer. 
A) IHC analysis of tissue microarrays. TMA were incubated with the anti-EXN11 polyclonal antibody The 
table reports the frequency of cancer tissues showing differential immunostaining versus corresponding 
normal samples. Immunostaining images of cancer and normal samples. B)  WB analysis of clinical 
samples. Total protein extracts from cryo-preserved colon and ovary biopsies of cancer (k) and normal (n) 
tissues from patients were analysed by  WB with anti-EXN11 or anti-actin antibodies. Arrows mark the 
EXN11 and actin bands. C) IHC analysis of liver metatastasis from CRC, stained with the anti-EXN11 
antibody. 
 
3.2.2. EXN11 has a marginal endogenous expression under in vitro standard growth of tumor cell 
lines 
Cancer cells, infiltrating cells and stromal cells secrete endothelial cell growth factors that 
modulate vascular network formation. Thus, we first assessed whether EXN11 is endogenously 
expressed under normoxic growth conditions in a panel of human cells by Q-RT-PCR, including: 
i) human cancer epithelial cells from different organs, such as breast (T47D, MCF7, MDAMB231, 
SKBR3), colon (Colo205, HCT15, HCT116), ovary (Ovcar3, Ovcar4, Ovcar8), and melanoma 
(A375, HS294T); ii) the human endothelial cell lines HUVEC, DMVEC and EPC; iii) cancer 
associated fibroblasts/myofibroblasts and M1-polarized macrophages. As shown in Figure 14A, 
41 
 
EXN11 transcript was successfully amplified from Ovcar8 cells while it was barely detectable in 
the other samples. In line with the data,  WB analysis of total protein extracts (25 µg per lane, 
derived from approximately 1x10
5
 cells) and culture supernatants (15 µl of 40-fold concentrated 
supernatants per lane, corresponding to 3x10
5 
cells) of the same cells using anti-EXN11 antibodies 
showed a faint EXN11 band in the cell culture supernatant of Ovcar8 (Figure 14B), which was not 
detectable in the other cells tested (Figure 14B represents exemplary data in HCT15 cells). EXN11 
expression was clearly detected by the anti-EXN11 antibody in culture supernatants of cell lines 
transfected with an EXN11 encoding plasmid, loaded in parallel as control.  
These results indicate that EXN11 endogenous expression is generally very low or negligible and 
suggest that specific environmental or regulatory factors might influence its expression. 
 
3.2.3 EXN11 expression is induced by hypoxia in cancer cells 
Since tumor angiogenesis is the result of a balance between stimulatory and inhibitory factors, an 
important aspect is to identify the regulatory or environmental conditions that promote the 
expression of ANGPL7 by malignant cells. To this purpose we exposed Ovcar8 and A375 cells to 
a series of stimuli and monitored EXN11 expression in the cell culture supernatant by  WB. Cells 
were either grown for 24 h under hypoxia (1% O2) or oxidative stress (500 μM H2O2), stimuli that 
induce structural and metabolic cell changes. In parallel, to mimic the effect of tumor 
microenvironment, cancer cells were also co-incubated for 24 h with the conditioned media from 
stromal cells known to be involved in cancer progression, such as cancer associated 
fibroblasts/myofibroblasts and M2-polarized macrophages.  WB analysis on the culture 
supernatant of the stimulated cells showed that EXN11 expression level was specifically up-
regulated in response hypoxia, whereas it was unchanged under oxidative stress (Figure 14B) an in 
any other tested conditions (not shown). EXN11 up-regulation in response to hypoxia was also 
confirmed by Q-RT-PCR on RNA samples extracted in parallel (Figure 14C). Similar results were 
obtained in HCT15 colon cells exposed to the same stimuli (data not shown). 
 
3.2.4. EXN11 is associated with exosomes 
Exosomes are cell-released vesicles that serve as vehicles of protein and nucleic acids and provide 
a route of communication between cancer cells and various stromal cells infiltrating the tumor 
interstitium. Recently, numerous studies have shown that exosomes affect several stages of 
tumour progression, including angiogenesis. We investigated the presence of EXN11 in the 
exosomial fraction of cancer cells by  WB. Exosomes were purified from the culture supernatant 
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of Ovcar8 cells by sequential differential centrifugations that yielded five centrifugation pellets, of 
which P1 represents the cellular pellets, P2-P4 are intermediate supernatant-derived pellets and P5 
is the final exosome-enriched pellet and protein extracts of P1 (20 µg/lane, corresponding to 
approximately 1x10
5
 cells), P4 and the final exosome pellet P5 (10 µg/lane, corresponding to 
2x10
7
 cells) were subjected to  WB with antibodies raised against the exosomial marker CD81, 
and with anti-EXN11 antibodies. CD81 was highly enriched in the exosomial fraction confirming 
the quality of the preparation. A band of 45 kDa was detected with anti-EXN11 antibodies, 
indicating that the protein at least partially associates with exosomes (Figure 14D). 
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Figure 14. EXN11 expression profile in human cells. 
A) EXN11 transcription analysis in human cells. EXN11 relative transcript level (RQ) was quantified in 
total RNA from different cell lines by q-RT-PCR vs MAPK gene and further normalized to the EXN11 RQ 
in Ovcar8 cells. B)  WB analysis of EXN11 expression in response to oxygen availability and oxidative 
stress. Ovcar8 and A375 cells (5 x10
6 
cells) were cultured for 24 h under normoxia (20% O2) or hypoxia 
(1% O2), or treated with H2O2 500 µM. The culture supernatant (20 ml) from each sample was concentrated 
40 fold, and 15 l were subjected to immunoblot with anti-EXN11 antibodies. C) EXN11 transcription in 
response to oxygen availability. EXN11 RQ was assessed in total RNA from Ovcar8 and A375 cells 
incubated under normoxia or hypoxia, using MAPK as internal standard. D) EXN11 association with 
exosomes. The exosomial fraction was purified from Ovcar8 cells by sequential centrifugations yielding 
five centrifugation pellets (P). P1 (cellular pellet), P4 (intermediated pellet), and P5 (exosome-enriched 
pellet) were subjected to WB with anti-EXN11 or anti-CD81 antibodies. 
 
3.2.5. EXN11 exerts pro-angiogenic activities on differentiated endothelial cells in vitro 
The formation of new blood vessels is a tightly regulated multi-step process that begins with the 
activation and migration of endothelial cells to chemotactic stimuli issued by the surrounding 
stroma. Extravasation of endothelial cells is followed by intense proliferation, as well as changes 
in morphology that generate primitive tubular structures from which the new vessel generates. 
Each of these phases may constitute an aspect of investigation in vitro (50,51). Thus, we 
investigated the EXN11 angiogenic activity by measuring its influence on the motility and 
invasiveness of different endothelial cell populations, as well as on their ability to reorganize and 
differentiate into capillary-like networks. We first assessed the effect of increasing concentrations 
of purified human recombinant EXN11 (ranging from 0.1 to 5 g/ml) on migration and 
invasiveness of the human umbilical vein endothelial cells (HUVECs) using a Boyden chamber 
assay. As shown in Figure 15A, HUVEC transmigration increased in a concentration dependent 
manner with respect to non-stimulated cells (approximately four-fold increase already at 0.1 g/ml 
of EXN11), reaching a plateau at 1g/ml. We next analyzed the EXN11 influence on the ability 
of HUVECs to organize into a tubular network by the Matrigel morphogenesis assay. As shown in 
Figure 15B, HUVEC incubated at 1 g/ml or higher concentrations of EXN11 showed an 
improved capacity to form capillary networks, compared to untreated cells. 
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Figure 15. Purified EXN11 has pro-invasive and pro-angiogenetic effects on HUVEC. 
A) Boyden Invasion assay. HUVEC (2.5 x 10
4
) were placed onto the upper compartment of the Boyden 
chamber in presence of medium containing different concentrations of purified EXN11 and incubated 
overnight at 37°C. Cell invasiveness was evaluated after Diff-Quick staining by counting cells in six 
randomly chosen fields. B) Capillary morphogenesis assay. 2 x 10
4
 HUVEC were plated on Matrigel-
coated 96-well plates and the tubular network formation was photographed 7 h after seeding. Results are 
shown as mean of three independent experiments performed in duplicate ± standard deviation. Asterisks 
mark EXN11 stimulated cells showing a significant difference (p < 0.05) vs untreated cells. Images 
representing the visual counting of each sample are reported below the graphs. 
 
The pro-angiogenic effects of EXN11 were further confirmed using the conditioned medium of 
A375 cells transfected with EXN11 (EXN11 CM), on both HUVEC and human dermal 
microvascular endothelial cells (DMVEC) (the latter represent a more physiological vascular cell 
model). The concentration of soluble EXN11 in the EXN11 CM was approximately 0.4 g/ml as 
opposed to 0.6 ng/ml of EXN11 found in CM of cells transfected with the empty vector (Mock 
CM). EXN11concentration in CM was estimated by densitometric analysis of  WB of EXN11 CM 
compared to different amounts of purified EXN11, and further confirmed by the Proseek system, a 
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PCR method based on the proximity ligation principle (not shown). EXN11 CM exerted pro-
migratory and pro-invasive effects on both HUVEC or DMVEC (Figure 16), as indicated by the 
1.5-2 fold increase in migration and invasiveness with respect to Mock CM. EXN11 CM also 
stimulated the formation of primitive tubular structures in matrigel tube assays, inducing about 2 
fold increase of tubular junctions (Figure 16). Similar phenotypic effects were observed using the 
CM of Ovcar8 and HCT15 cells transfected with EXN11 (data not shown). 
 
Figure 16. EXN11 secreted by transfected cells has pro-angiogenetic effects on differentiated endothelial 
cells. For Boyden migration and invasiveness assays 2.5 x 10
4 
HUVECs or 2 x 10
4 
MVECs were placed 
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onto the upper compartment of the Boyden chamber in presence of medium conditioned from transiently 
transfected A375 (Mock CM and EXN11 CM) and incubated overnight at 37°C. Capillary morphogenesis 
assay was carried out placing 2 x 10
4
 HUVECs or DMVECs on Matrigel-coated 96-well plates and the 
tubular network formation was photographed 7 h after seeding. As controls, cells were also stimulated with 
VEGF (10 ng/ml). VEGF had a neutral effect on HUVEC and a pro-angiogenic activity on DMVEC. For 
each experiment, results represent mean and standard deviation obtained from 3 independent experiments 
performed in duplicated. Asterisk marks a statistically significant difference (p < 0.05) vs Mock C.M 
treated cells. Images of the visual counting of each samples are reported below the graphs. 
 
3.2.6. The human endothelial progenitor cells respond differently to the stimulation induced by 
EXN11 
We then investigated whether EXN11 exerts its pro-angiogenetic effect on EPCs. EPC are bone 
marrow-derived progenitor cells that, once recruited to neo-vascularization sites into the vascular 
endothelial lining, differentiate in situ into mature endothelial cells. In adults EPC participate to 
the assembly of newly-forming blood vessels, and a growing number of studies report that EPC-
dependent vasculogenesis plays an important role in cancer progression. Since several anti-
angiogenic therapies, or antiangiogenic factors as endostatin, have been ineffective on EPC-
mediated vasculogenesis, vasculogenetic factors are becoming potential attractive targets for 
developing of novel cancer therapeutics. We analyzed the EXN11 CM effect on EPCs migration, 
invasiveness, and morphogenesis, as described above. As shown in Figure 17, neither cell motility 
(panels A and B, respectively) nor the ability to generate tubular structures in vitro (panel C) were 
significantly stimulated by treatment with EXN11 CM. This result suggests that EXN11 exerts its 
angiogenic activity on cells, such as HUVEC and DMVEC, already differentiated towards 
endothelial lineage, while has little effect on endothelial cell progenitors. 
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Figure 17. EXN11 secreted by transfected cells does not influence angiogenetic phenotypes of endothelial 
progenitor cells.For Boyden cell migration and invasiveness assays (A and B, respectively) 20 x 10
4
 EPC 
were seeded into the upper chamber of Boyden chambers with EXN11 C.M. or Mock C.M. Cells were 
allowed to migrate for 16 h through the filter toward the lower chamber filled with complete growth 
medium. Capillary morphogenesis angiogenesis (C) was carried out placing 2 x 10
4
 EPCs (C) or DMVECs 
(F) on Matrigel-coated 96-well plates and the tubular network formation was photographed 7 h after 
seeding. As controls, cells were also stimulated with VEGF (10 ng/ml). Results are representative of 3 
independent experiments. Images of the visual counting of each samples are reported below the graphs. 
 
3.2.7. EXN11 promotes vascularization in the mouse matrigel sponge assay 
Finally, we confirmed the EXN11 pro-angiogenic activity by measuring its ability to promote 
vascularization in mice, using the Matrigel sponge assay. Briefly, Swiss male mouse groups were 
injected subcutaneously into either of the two flanks with unpolymerized matrigel containing 
purified recombinant human EXN11 or Medium (4 mice per group). Four days after injection 
mice were killed and the vessel formation was evaluated in the matrigel sponges by visual 
inspection. 8/8 EXN11-containing matrigel plugs showed the formation of dendritic branched 
vessels which extended toward the center of the sponge whereas controls showed only sketches of 
vessels at the periphery of the sponge (Figure 18A), thus confirming the EXN11 ability to act as 
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angiogenic factor in vivo. Quantitation of vessels formed within sponges (Figure 18B) and 
confirmed the ability of EXN11 to act as angiogenic factor in vivo. 
 
 
Figure 18. EXN11 stimulates vessel formation in the mouse matrigel sponge assay. 
Swiss wild type male mice were implanted into both flanks with the Matrigel sponges containing purified 
EXN11 (10 g/ml) or matrigel alone and four days after injection sponges were excised and photographed. 
The new vessel formation was quantified by visual inspection. A) Microscopic enlargements of EXN11-
injected sponges and negative controls. B) Quantification of microvessel density. The effect induced by 
EXN11 was quantified by counting the vessel branching in EXN11-injected and negative control sponges. 
Asterisk mark the statistical difference between the samples (P<0.02, determined by Student’s T test). 
  
49 
 
4. DISCUSSION AND FUTURE PERSPECTIVES 
Progress in prevention and therapy has led to remarkable decreases in mortality and death rates 
due to cancer. Basic research has reached amazing advancements in different areas, such as the 
genetic basis of cancer, understanding the regulation of signaling pathways and their biochemical 
components, new insights in the communication between cancer cells and normal cells, and the 
elucidation of the mechanisms of metastasis. The research progress has pushed the research of 
molecularly targeted therapies, directed against individual signaling components activated in 
cancer cells, that have improved the success of treatment (1). Notwithstanding the impressive 
success in the field, there is still a great demand for new validated cancer markers are needed to 
improve diagnosis, patient’s stratification, predict the disease outcome, help physicians to 
rationalize the use of cancer therapies and monitor their efficacy. Similarly, there is an urging 
need for novel drug targets, to be used alone or in conjunction with existing therapies.  
This study addresses these needs by characterizing two novel cancer markers and potential 
therapeutic targets previously identified by Externautics, in collaboration with the European 
Institute of Oncology.  
 
Concerning EXN6, this rather unknown protein that seems to be very attractive for therapeutic 
applications. Our data show that it is mainly detected in ovary and breast cancers, and with lower 
frequency in colon and lung cancers. By confocal microscopy and FACS analyses, we showed that 
it is a surface exposed protein, thus it could be target of novel drugs, such as small molecules and 
mAbs. Moreover, gene silencing experiments aimed at understanding its role in cancer processes 
relevant for tumor growth and progression showed that loss of EXN6 expression clearly impairs 
cell proliferation and invasiveness, strongly suggesting that EXN6 is a key component of cancer 
signaling pathways. Experiments to understand the molecular pathways in which it is involved are 
ongoing.  
This study also led to the selection of anti-EXN6 mAbs with potential therapeutic applications. 
Within a group of mAbs that were generated and characterized, five were able to bind the surface 
of ovary and breast cancer cell lines. Of utmost interest are two mAbs that, after binding on the 
cell surface, are efficiently internalized by cancer cells. This important property make them 
amenable to the generation of ADC for EXN6 targeted therapy. Moreover, the evidence that they 
have limited reactivity in a panel of 33 normal human tissues could predict an acceptable 
tolerability and safety profile in vivo. The mAb elucidation of the mechanism of internalization, 
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under study, will be a necessary additional information to rationalize the ADC strategy and the 
selection of the most appropriate linkers and drugs to be conjugated with the antibodies.  
In addition to internalization, we also found that one mAb also shows ADCC activity. Thanks to 
its dual activity, this mAb could be exploited either as naked or as ADC. Efficacy studies in 
xenograft mouse cancer models are currently ongoing to evaluate its ability to prevent, delay the 
tumor formation or interfere with its progression is assessed. Moreover, experiments are ongoing 
to identify of the molecular pathways perturbed by the mAb interaction with cancer cells.  
 
Concerning EXN11, this protein shows high structural homology with ANGPTLs, proteins, with 
which it shares a coiled-coil domain at the N-terminus and a fibrinogen-like domain at the C-
terminus. After approximately a decade from their first identification, most members of this family 
are emerging as central players of different cell processes and human diseases. Several ANGPTL 
proteins potently modulate angiogenesis (42-45), though for some of them the effect remains 
controversial. ANGPTLs are also involved in other processes independently from angiogenesis, 
such as augmentation of energy expenditure, induction of inflammation, and metabolism (45,46) 
 Our study provides information on the biological role of EXN11 by showing that i) it is 
differentially expressed in certain types of cancer, and ii) it acts as pro-angiogenic and 
vascularization factor. By immune-histochemical analysis of paraffin-fixed samples and  WB 
analysis of fresh clinical samples, EXN11 was found over-expressed in colon cancer and, at lower 
frequency, in breast and ovary cancers, while it appeared to be expressed at basal level in prostate 
and lung cancer. Moreover, the protein was also over-expressed in liver metastasis from CRC 
cancer suggesting that it could be involved in cancer dissemination at distant sites. 
Based on its homology to ANGPTLs, we investigated the EXN11 role angiogenesis. Angiogenesis 
is an essential step during the initial stages of tumor development, in which cancer cells secrete 
growth factors to promote tumor neovascularization and improve the otherwise inadequate 
vasculature. Enhanced expression of proangiogenic genes can activate quiescent microvascular 
endothelial cells, causing them to dissociate from the cell-cell junctions, migrate into the 
perivascular space, proliferate extensively, and form tubular structures. 
We assessed the role of EXN11 in angiogenesis by evaluating its effect on different endothelial 
cell populations. They include HUVEC and DMVEC, derived from large wall vessels and dermal 
microvasculature, respectively, and extensively used as models of fully differentiated endothelial 
cells to assess de novo angiogenesis. Moreover, since recent evidence indicates that the de novo 
generation of endothelial cells from bone marrow-derived circulating endothelial cell precursors 
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(EPC) also contributes to the vasculature formation (a process referred to as vasculogenesis) 
especially under pathological conditions including cancers (52,53) we also investigated the 
EXN11 effect on EPC. 
Overall, our data include EXN11 among the factors capable of regulating vessel organization and 
maturation of endothelial cells but not of bone marrow-derived undifferentiated precursors. 
Indeed, we consistently showed that EXN11 enhances migration and capillary network formation 
ability of HUVEC and DMVEC, whereas it does not influence these phenotypes in EPC, 
indicating that differentiated and progenitor endothelial cells respond differently to this protein. A 
hypothesis that needs appropriate investigation is that the EXN11 receptor is expressed only in a 
final step of differentiation process of endothelial cells. Overall, EXN11, although not effective on 
EPC-dependent vasculature formation, is very active in promoting vascular organization of cells 
that have already undergone differentiation towards endothelial lineage, and could represent an 
attractive therapeutic target for anti-angiogenic tumor therapy. 
 
Since the actual regulation of tumor angiogenesis is the result of a fine balance between 
stimulatory and inhibitory factors secreted by cancer cells, infiltrating cells and stromal cells in 
response to environmental stimuli, we elucidated the conditions that promote EXN11 expression. 
In agreement with previous evidence (54) our profile analysis of EXN11 basal expression in a 
panel of cancer epithelial, endothelial and stromal cell lines showed that, in general, EXN11 has a 
very low expression under standard conditions. This evidence further corroborates the notion that 
EXN11 expression is not a common event in human cancer cells and might be tightly regulated in 
response to specific parameters. By exposing cancer cell lines to different stimuli reproducing 
some aspects of cancer environment we found that, similarly to ANGPTL2 and ANGPTL4 
(55,56), EXN11 is specifically stimulated by hypoxia, the predominantly stimulus that induces the 
aberrant expression of pro-angiogenic factors. We also observed that other environmental stimuli, 
like exposure to cancer-associated fibroblasts or M2 polarized macrophages, known to rapidly 
modulate other angiogenic factors as VEGF, FGF-2 or IL-8, are ineffective in eliciting EXN11. 
 
The regulatory mechanisms underlining the EXN11 response to hypoxia and angiogenesis need to 
be elucidated. Bioinformatic annotations of human EXN11 promoter available in public web 
databases (http://www.genecards.org) do not reveal canonical core binding sites of the hypoxia-
inducible factor 1-alpha (HIF-1a), the major regulator of the transcriptional response to oxygen 
availability, suggesting that HIF-1 does not exert a direct regulation on EXN11 expression. 
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Recently, an integrative approach combining both computational and experimental strategies to 
HIF-1-target genes did not categorize EXN11 among the genes involved in the core response to 
hypoxia (57). Instead, the EXN11 promoter analysis identified two major cis-regulatory elements. 
In particular, four Lymphoid-Enhancing Factor/T-Cell Factor LEF (LEF/TCF)-binding sites are 
present in the promoter region (58). LEF/TCF proteins belong to the family of architectural 
transcription factors that control developmental processes and have an important role in 
oncogenesis. Since LEF/TCF proteins are typically activated by the WNT/ß-catenin signaling 
pathway, a key player in oncogenesis and also involved in many aspects of normal and 
pathological angiogenesis (59), we speculate that WNT/ß-catenin exerts a control on EXN11 
expression in cancer. Interestingly, the promoter of the human EXN11, but not the mouse 
ortholog, also contains four interferon-stimulated response elements (ISREs) suggesting that 
Interferon could stimulates the transcriptional activity of the human promoter in vitro. The 
possible existence of a cross talk between LEF/TCF and IFN on EXN11 expression deserves 
further dedicated studies. 
 
Another open question is how EXN11 influences cancer angiogenesis. Interestingly, here we 
showed that this protein, similarly to ANGPTL4 (www.exocarta.org), is at least partially 
associated with exosomes released by cancer cell lines. Thus, an interesting hypothesis, currently 
under investigation, is that, like other ANGPLTs, EXN11 could be released in the circulation of 
oncologic patients, and could function in an endocrine manner, both in the soluble and in 
exosome-associated forms. 
 
A final aspect, beyond the purpose of this study, is related to the EXN11 receptor molecule on 
target cells. Most members of the ANGPTL family are currently considered orphan ligands 
because information regarding their potential binding partners is lacking. To date, integrins have 
been regarded as major functional interactors of ANGPTLs. For instance, 1 integrin is a 
receptor for ANGPLT2 and ANGPTL4 (46,56). In an elegant study Marchiò et al., by screening a 
phage displayed random peptide library, found that hepatic ANGPTL6 protein binds a complex of 
E-cadherin and 6 integrin on the surface of CRC by involving a binding site mimicking the 
structure of peptide CGIYRLRS, and demonstrated that such interaction drives liver homing and 
colonization by CRC cells (60). Moreover, these authors provide a possible molecular mechanism 
for CRC metastasis by showing that that the angiopoietin-like 6-mimicking peptide has anti-
metastatic effects in preclinical models of human CRC. They also describe different proteins 
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sharing similarity with the metastasis-specific peptides, and speculate that the angiopoietin-like 
6/6 integrin/E-cadherin system is part of an interconnected network, in which several proteins 
interact with different molecular partners based on their availability, combination and affinity. 
Since similar peptide motifs are also found in EXN11 sequence, an intriguing hypothesis is that 
also this protein participates to the same functional complex with E-cadherin and 6 integrin. 
Experiments to elucidate this aspect are in progress.  
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5. MATERIALS AND METHODS 
Chemicals, reagents and cell cultures  
Unless specified, all reagents were obtained from Sigma. Restriction enzymes and DNA 
modification enzymes were from New England Biolabs. DNA and RNA extraction kits were from 
QIAGEN. Antibodies for  WB analysis were from BD Biosciences. VEGF-A was purchased from 
PeproTech. Matrigel Basement Membrane was from BD Biosciences. Human epithelial cells 
were obtained from the ATCC collection and cultured under ATCC recommended conditions. 
Human umbilical vein endothelial cells (HUVEC) were purchased by the European Collection of 
Cell Cultures. Microvascular endothelial cells (DMVEC) and endothelial progenitor cells (EPC), 
were kindly provided by Prof. M. Del Rosso of Department of Clinical Physiopathology, 
University of Florence. DMVECs have been isolated from biopsy samples of skin of hands of 
healthy patients, while human UCB samples of health newborns were used as a source of EPCs, 
as previously described (61,62). All endothelial cell lines were cultered on gelatin 1%-coated 
dishes in complete endothelial cell growth medium (EGM-2 BulletKit, Lonza), which includes 
endothelial basal medium plus the SingleQuots Kit (hydrocortisone, human fibroblast growth 
factor B, VEGF, LongR3 insulin-like growth factor 1, ascorbic acid, human epidermal growth 
factor, GA-1000, and heparin), supplemented with antibiotics (100 UI/ml penicillin, 100 µg/ml 
streptomycin) and 2% FBS for HUVECs or 10% FBS for DMVEC and EPC. Endothelial cell 
types were used between the third and tenth passages in vitro. A375 human melanoma cells were 
purchased from ATTC. Cells were grown in Dulbecco’s modified Eagle’s medium supplemented 
with 10% FBS, 4mM L-glutamine and antibiotics (100 UI/ml penicillin, 100 µg/ml streptomycin). 
Escherichia coli BL21(DE3) was grown aerobically in Luria broth (LB) medium (Difco) at 37°C. 
When appropriate, ampicillin (Amp, 100 µg/ml) and isopropyl-β-D-galactopyranoside (IPTG; 
1mM) were added to the medium. 
 
Generation of anti-EXN11 and antiEXN6 mouse polyclonal antibodies. 
Suitable fragments of the EXN11 and EXN6 coding regions (CDS) were selected for cloning / 
expression using bioinformatics tools. The leader sequence for secretion was replaced with the 
ATG codon to drive the expression of the recombinant proteins in the cytoplasm of E. coli. For 
cloning, cDNAs were generated by reverse transcription from total RNAs (Euroclone) of human 
tissues (bone marrow, fetal brain, placenta and testis) and pooled. Gene fragments were amplified 
from cDNA pools using specific primers (designed using Primer3 Software, Premier Biosoft 
International) so as to fuse a 10 histidine tag sequence at the 3’ end, annealed to in house 
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developed vector (p2N) derivative of vector pSP73 (Promega) adapted for the T4 ligation 
independent cloning method (10) and used to transform E.coli NovaBlue cells recipient strain. E. 
coli transformants were plated onto selective LB plates containing 100 µg/ml ampicillin (LB 
Amp) and positive E.coli clones were identified by restriction enzyme analysis of purified plasmid 
followed by DNA sequence analysis. EXN11 and EXN6 recombinant proteins were purified from 
the inclusion bodies. Briefly E.coli BL21(DE3) cells harboring the plasmid were inoculated in 50 
ml of ZYP-5052 growth medium and grown at 37°C for 24 hours. Afterwards, bacteria were 
harvested by centrifugation and lysed into 10 ml of B-Per Reagent (Pierce) containing 1 mM 
MgCl2, 10 units/ml of DNAse I (Sigma), and 1 mg/ml Lysozime (Sigma). After 30 min at room 
temperature under gentle shaking the insoluble inclusion bodies were collected by centrifugation 
at 30.000 x g for 40 min at 4°C. To solubilize inclusion bodies, the pellet was resuspended in 10 
ml of 6M guanidine hydrochloride, 1 mM Tris(2-carboxyethyl)-phosphine hydrochloride (TCEP) 
(Pierce), 40 mM Tris-HCl pH 8. After clarification by centrifugation at 30.000 g for 30 min, the 
supernatant was loaded on 0.5 ml columns of Ni-activated Chelating Sepharose Fast Flow resin 
(GE-Healthcare). After wash of the resin with 10 column volumes of 6M urea, 60 mM imidazole, 
0.5M NaCl, 1 mM TCEP, 50 mM TRIS-HCl pH 8, recombinant proteins were eluted with the 
same buffer containing 500 mM imidazole. Proteins were analysed by SDS-Page and their 
concentration was determined by Bradford assay using the BIORAD reagent (BIORAD) with a 
bovine serum albumin standard according to the manufacturer's recommendations. 
To generate anti-EXN11 and EXN6 polyclonal sera, the purified proteins were used to immunize 
CD1 mice (6 week-old females, Charles River laboratories, 5 mice per group) subcutaneously with 
3 protein doses of 20 micrograms each, at 2 week-interval. Freund's complete adjuvant was used 
for the first immunization, while Freund's incomplete adjuvant was used for the two booster doses. 
Two weeks after the last immunization animals were bled and sera collected from each animal 
were pooled. 
 
Immunohistochemistry 
The capability of the anti-EXN11 and anti-EXN6 polyclonal antibodies to recognize their target 
proteins in tumor samples was assessed by immunohistochemistry. Tissue Micro Array (TMA) 
were generated using formalin-fixed, paraffin-embedded samples for CRC (adenocarcinoma), 
ovarian cancer (serous and endometroid), breast cancer (ductal and invasive lobular carcinoma), 
lung cancer (adenocarcinoma, squamous cell carcinoma), prostate cancer (acinar carcinoma), that 
were selected from the archives at the IEO (Istituto Europeo di Oncologia, Milan, Italy). Normal 
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tissues were defined as microscopically normal (non-neoplastic) and were generally selected from 
specimens collected from the vicinity of surgically removed tumors (63). Patients were 
consecutive cases selected based on tumor size (tumors having a maximum diameter greater than 
2 cm were selected). Corresponding whole tissue sections were examined to confirm diagnosis 
and tumour classification, and to select representative areas in donor blocks to be cored. Briefly, 
each TMA slide included tumor tissue cores representative of 5 different well pedigreed patients 
for each cancer type, and an equal number of matched normal tissue cores from the same patients 
in duplicate. The direct comparison between tumor and normal tissues of each patient allowed the 
identification of antibodies that differentially stain tumor cells and provided indication of target 
expression in the tumor under investigation. TMA production was performed essentially as 
previously described (63). Briefly, a hole was made in the recipient TMA block. A cylindrical 
core tissue sample (1 mm in diameter) from the donor block was acquired and deposited in the 
recipient TMA block. This was repeated in an automated tissue arrayer “Galileo TMA CK 3500" 
(BioRep - Milan) until completion of the TMA design. TMA recipient blocks were baked at 42°C 
for 2 h prior to sectioning. Two- to 3-micron thick sections were cut from the TMAs and placed 
onto poli-L-lysinated glass slides for immunohistochemical analysis. Moreover, 20 clinical 
specimens of liver metastasis from CRC, selected from the archives at the Istituto di Candiolo - 
IRCCS (Candiolo, Italy) were analyzed by traditional IHC methods. 
Automated immunohistochemistry was performed as previously described (63). Briefly, the glass 
slides were heated for 30 min at 60°C, de-paraffinized in xylene (2 x 15 min) using the Bio-Clear 
solution (Midway. Scientific, Melbourne, Australia), and re-hydrated in graded alcohols. For 
antigen retrieval, slides were immersed in 0.01 M Na-citrate buffer, pH 6.0 at 99°C for 30 min, 
placed in an automatic immunostainer (Autostainer (R) Dako, Glostrup, Denmark)) and 
endogenous peroxidase was initially blocked with 3% H2O2, for 5 min. Slides were then blocked 
in Dako Wash Buffer containing 5% bovine serum albumin (BSA) and subsequently incubated 
with the anti-EXN11 mouse polyclonal antibodies for 30 min (dilution 1:200 in Dako Real 
TM
 
dilution buffer). After washing with Dako wash buffer, slides were incubated with the goat anti-
mouse peroxidase conjugated Envision(R) detection reagent (Dako) for 30 min at room 
temperature. Finally, diaminobenzidine and the substrate chromogen (Dako) was used to visualize 
the reaction and Harris hematoxylin (Sigma Aldrich) was used for counterstaining. The slides 
were mounted with Pertex(R) (Histolab). Staining results were evaluated by a trained pathologist 
at the light microscope, and an IHC score was assigned corresponding to the percentage of 
immunostained cells (from 0 to 100%) multiplied by the intensity of staining (from 1 to 3). 
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Individual values and combined scores (from 0 to 300) were recorded in a custom-tailored 
database, which also included the subcellular localization of the immunoreactivity (membranous, 
cytoplasmic, nuclear). Digital images of the immunocytochemical findings were taken at a Leica 
DM LB light microscope, equipped with a Leica DFC289 color camera. 
 
 WB analysis of clinical samples  
Cryo-preserved normal and cancerous samples (10 mg) selected from the IEO archives from 
breast, ovary and colon were homogenized by mechanic tissue disruption in 1 ml buffer 
containing 40 mM TRIS-HCl, 1 mM Tris(2-carboxyethyl)-phosphine hydrochloride (TCEP, 
Pierce) and 6M guanidine hydrochloride, pH 8. After clarification 15’ at 14,000xg, the protein 
concentration was quantified by Bradford assay (BIORAD). After, 400 g of protein extracts were 
methanol precipitated, washed with 70% ethanol and resuspended in Laemmli buffer containing 
DTT. 20g of total protein extracts were loaded on pre-cast SDS-PAGE gradient gels (NuPage 4-
12% Bis-Tris gel, Invitrogen) under reducing conditions, followed by electro-transfer to 
nitrocellulose membranes (Invitrogen) according to the manufacturer’s recommendations. The 
membranes were blocked in blocking buffer composed of 1x PBS-0.1% Tween 20 (PBST) added 
with 10% dry milk, for 1 h at room temperature, incubated with the anti-EXN6, the anti-EXN11 
pAbs or with anti-actin Ab diluted 1:1000 in blocking buffer containing 1% dry milk and washed 
in PBST-1%. The secondary HRP-conjugated antibody (goat anti-mouse immunoglobulin/HRP, 
Perkin Elmer) was diluted 1:5000 in blocking buffer, and chemiluminescence detection was 
carried out using a Chemidoc-IT UVP CCD camera (UVP) and the Western Lightning
TM
 
Cheminulescence Reagent Plus (Perkin Elmer), according to the manufacturer’s protocol. 
 
Cell transfection 
For transfection experiments, the EXN11 and EXN6 encoding plasmids were generated by PCR 
amplifying the full length gene coding regions with specific primer pairs, and the PCR products 
was cloned into plasmid pcDNA3.1D (Invitrogen) and sequence verified. For transfection, the 
indicated cell lines were plated in 100-mm cell culture dishes in 6-well plates (1x10
6
 or in 400,000 
per well, respectively) were transiently transfected with 4 micrograms of the EXN11 or the EXN6 
encoding plasmids and with the empty vector as negative control (mock) using the Lipofectamine-
2000 transfection reagent (Invitrogen) according to the manufacturer’s protocol. The enhanced 
green fluorescent protein (EGFP) was co-transfected with empty vector (Mock) or plasmid DNA 
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encoding EXN6 or EXN11. The efficiency of transfection was valuated thereby fluorescent 
microscopy. After 24 hours, cells and culture supernatants were collected for expression analysis. 
 
Gene silencing,  
The indicated cancer cell lines (2x10
5 
cells in 6wells) were transfected with 10 mM of specific 
EXN6 siRNAs or irrelevant siRNA (QIAGEN) using the HiPerfect transfection reagent. After 48 
or 72 hours, cells were collected for expression or phenotypic analyses.  
 
Transcription analysis  
The marker expression was analyzed at RNA level in transfected and untreated cell lines by Q-
RT-PCR. Total RNA was extracted from the indicated cell lines and samples using the RNAeasy 
mini kit (QIAGEN) following the manufacturer's protocol and 5 µg of it were reverse transcribed 
using Superscript III Reverse Transcriptase (Life Technologies) with oligo dT. Triplicate cDNA 
samples from each cell line (equal to 50 ng RNA/sample) were subjected to real-time Q-PCR 
using the Quantitect SYBR Green PCR kit (QIAGEN), and commercially available primers and 
analysed with the One-Step Plus Q-RT_PCR equipment (Applied Biosystems). To control slight 
variations in the amount of RNA loaded into the PCR reactions, the difference in Ct (ΔCt) 
between samples were normalized by detracting the average Ct values of the housekeeping genes 
GAPDH.  
 
 WB analysis 
For  WB analysis of cancer cell lines, cell monolayers were detached with PBS-0.5 mM EDTA 
and lysed by several freeze-thaw passages in PBS-1% Triton. Total protein extracts (25g 
corresponding to approximately 2+10
5
 cells) and concentrated supernatants (normalized on 
number of cells), were loaded on pre-cast SDS-PAGE gradient gels (NuPage 4-12% Bis-Tris gel, 
Invitrogen) under reducing conditions and subjected to  WB with anti-EXN11 and anti-EXN6 
polyclonal and mAbs, as described. 
 
Surface localization analysis  
FACS 
For flow cytometry analysis of EXN6 localization, cells (2x10
4
 per well) were pelletted in 96 U-
bottom microplates by centrifugation at 200 x g for 5 min at 4°C and incubated for 1 hour at 4°C 
with the appropriate dilutions of anti-EXN6 antibodies. The cells were washed twice in PBS-5% 
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FCS and incubated for 20 min with the appropriate dilution of R-Phycoerythrin  
(PE)-conjugated secondary antibodies (Jackson Immuno Research, PA, USA) at 4°C. After 
washing, cells were analysed by a FACS Canto II flow cytometer (Becton Dickinson). Data were 
analyzed with FlowJo 8.3.3 program. 
 
Confocal microscopy 
Cells were plated on glass cover slips and after 48 h were washed with PBS and fixed with 3% 
paraformaldheyde solution in PBS for 20 min at RT. Then, after
 
extensive washing in PBS, cells 
were incubated with the appropriate antibodies overnight at 4°C (1:200), before or after 
permeabilization with 0.01% BriJ96® (Fluka). Cells were then stained with Alexafluor 488-
labeled goat anti-mouse antibodies (Molecular Probes). DAPI (Molecular Probes) was used to 
visualize nuclei. The cells were mounted with glycerol plastine and observed
 
under a laser-
scanning confocal microscope (LeicaSP5). 
 
mAb Internalization  
For Flow cytometry analysis of mAb internalization T47D and Ovcar3 cells were incubated with 
the anti-EXN6 mAbs or irrelevant mAb control (10 micrograms/ ml) for 30’ at 4°C to allow 
antibody binding on the cell surface. Then cells were washed with PBS-5% FCS to remove 
unbound antibody and shifted to 37°c for 1 hour. At time points, cells were incubated for 20 min 
with the appropriate dilution of R-Phycoerythrin (PE)-conjugated secondary antibodies at 4°C. 
After washing, cells were analysed by a flow cytometer and the data were analyzed, as described. 
For confocal microscopy analysis the same cells were plated on microscope cover-slips and after 
48 h were washed with PBS. Cells were incubated with the mAbs for 1 hour at 4°C (10 
micrograms/ ml) and subsequently shifted at 37°C. Cells were then fixed with 10 minute 
incubation with 90% cold methanol and stained with Alexafluor 488-labeled goat anti-mouse 
antibodies and DAPI, as described. 
 
FabZAP assay 
T47D cells were plated in 96w plates (2000 cells/w) and incubated with the anti-EXN6 mAbs or an 
irrelevant mAb control at different concentrations (from 1 to 40 g/ml) for 30’ at 4°C to allow antibody 
binding on the cell surface. Then cells were washed with PBS-5% FCS to remove unbound antibody, added 
with FabZAP (Advanced Targeting System) at the conditioned suggested conditioned and shifted to 37°c 
and 5% CO2 for 72 hours. Residual viability was measured by the MTT assay. 
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EXN11 expression stimulation in human cells 
The microenviroment influence on EXN11 expression in cancer cells was investigated by 
exposing A375, OVCAR8 and HCT15 cells to different stimuli. The effect of oxygen availability 
and oxidative stress cells was assessed on cells maintained for 24 h in hypoxia condition (1% O2), 
or treated with H2O2 500 µM for 24h and analyzed by  WB. The effect induced by the conditioned 
media (CM) of cancer associated fibroblasts/myofibroblasts and M1-polarized macrophages on 
A375, OVCAR8 and HCT15 cells was also assessed. Briefly, human monocytes were obtained 
from normal donor buffy coat by gradient centrifugation using Ficoll (Histopaque-1077). Non-
adherent cells were removed and purified monocytes were incubated for 7 days in RPMI 1640 
supplemented with 10% FBS and 50 ng/ml macrophage-colony stimulating factor (M-CSF) to 
obtain macrophages. M0 cells were obtained by treating with serum-free medium for 48h. M1 
macrophages were polarized by stimulating overnight with LPS (100 ng/ml) (Peprotech) and IFNγ 
(100 ng/ml) (Peprotech). HDFs were grown to sub-confluence and treated for 24 h with 10 ng/ml 
rTGF-b1 in normoxic (20% oxygen) or hypoxic conditions (1% O2). Fresh serum-free medium 
was added for additional 24 h before collection of CM. Total RNA and protein extracts were 
extractd for transcription and  WB analysis, respectively. 
 
Exosomes preparation and analysis 
Exosomes from cell culture supernatants were isolated by differential centrifugation as described 
(64). Briefly, 1x10
8
 OVCAR8 cells were cultured in 400 ml of serum-free medium (PFHM-II 
Gibco-Life Technologies) for 24 h and then centrifuged at 200xg for 10 min (pellet P1). The 
supernatant was collected and centrifuged twice at 500g for 10 min (pellet P2). The second 
supernatant was sequentially centrifuged at 2,000xg twice for 15 min (pellet P3), once at 10,000xg 
for 30 min (pellet P4), and once at 70,000xg for 60 min (pellet P5), using a SW28 rotor (Beckman 
instruments, Inc.). The cellular pellet P1 was solubilized in 1 ml of C-RIPA buffer (50 mM Tris-
Hcl pH7.5, 150 mM NaCl, 1% Nonidet P-40; 2mM EGTA, 1 mM orthovanadate, 0.1% SDS, 
0.5% Na-deoxycholate, 1 mM phenyl-methane-sulphonylfluoride, 10 g/ml leupeptin, 10 g/ml 
aprotinin) while each of the supernatant-derived pellets P2–P5 were solubilized in 0.5 l of the 
same buffer. After clarification, the protein concentration of each sample was determined by 
Bradford. 20 g of P1 extract and 10g of P2-P5 extracts (corresponding to approximately 2x105 
and 2x10
7
 cells, respectively) were loaded on SDS-PAGE (4-12%) and  WBting with the anti-
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EXN11 polyclonal antibody. As quality controls of the exosomial preparation, the blots were also 
incubated with antibodies targeting the exosomial marker CD81. 
 
Preparation of conditioned media (CM) for phenotypic assays 
CM for phenotypic assays were mainly obtained from A375 transiently transfected with empty 
vector (Mock CM), or with plasmid encoding EXN11 (EXN11 CM). 24 h after transfection, 
medium was removed and replaced with endothelial basal medium (EGM-2 deprived of FBS and 
all growth factors) and incubation was prolonged for additional 24 h. Then medium was harvested, 
clarified by centrifugation, and used freshly for conditioning endothelial cell lines. 
 
Quantification of EXN11 secreted in cell CM 
The EXN11 concentration in EXN11 CM or mock CM was first measured in solution with a 
mouse polyclonal anti-EXN11 antibody and the Proseek2 kit (Olink Bioscience, Uppsala, 
Sweeden), an assay based on the antibody-based proximity extension assay (65). EXN11 
quantification was also confirmed by densitometric analysis of immunoblot. Different amounts of 
EXN11 CM were subjected to  WB and the intensity of the EXN11 band was compared with the 
corresponding band of defined amounts of purified protein. Both analysis indicated that EXN11 
concentration was approximately 0.5-1 g per ml in EXN11 CM and it was undetectable in mock 
CM. 
 
Capillary morphogenesis assay 
The effects of EXN11 on the ability of endothelial cells to reorganize and differentiate into 
capillary-like network, were assessed thereby Matrigel morphogenesis assay. Briefly, 50 µl of 
Matrigel matrix growth factor reduced (1 mg/ml) was added into wells of a 96-well plate and 
polymerized for 1 h at 37°C. Endothelial cells, after 24 h of incubation in basal EGM-2 medium, 
were washed once with PBS, harvested by trypsinization and collected by centrifugation. Then, 
cells were resuspended in 200 µl of EGM-2 containing different concentrations of purified EXN11 
or conditioned medium (Mock CM or EXN11 CM) and placed into Matrigel-coated wells (2x10
4 
HUVEC, or DMVEC, or EPC/well). Cells diluted in EGM-2 basal medium supplemented with 
VEGF 10 ng/ml were used as positive control. After 6h-incubation on Matrigel at 37°C, network 
formation was observed using a phase contrast microscope equipped with CCD optics and a 
digital analysis system. Each experiments was carried out in duplicate. Results are expressed as 
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mean of joint numbers counted in four randomly chosen fields for well, and averaged from at least 
3 independent experiments. 
 
MTT assay 
The MTT assay was used as a to assess cell viability and proliferation in cancer cell lines 
transfected with EXN6 siRNA. After 48 hours cells were serum starved and seeded into 96-well 
plates (2 × 10
5
 cells/ml) in the presence of medium, with or without 2%FCS and EGF. The MTT 
assay was performed using a commercially available MTT assay kit (Roche Diagnostics, 
Indianapolis, IN) according to manufacturer's instructions. The remaining viable cells with MTT 
dye uptake were determined by measuring the optical density at 490 nm in an enzyme-linked 
immunosorbent assay reader. Values shown were averaged of at least six measurements, and 
represented three replicated experiments.  
 
ADCC-reporter gene assay 
The T47D cell line was seeded at 10000 cells per well in a 96 well opaque tissue culture plate. 
Anti-EXN6 mAbs antibody and irrelevant isotype controls (IgG1, IgG2a) were serially diluted and 
incubated with the T47D cells for approximately 1 h at 37°C, 5% CO2. Following incubation, 
Jurkat NFAT luciferase reporter cells, were added to the T47D/antibody mixture at 30000 cells per 
well. The mixture was incubated for approximately 4 h at 37°C, 5% CO2, and then measured for 
luciferase production using a luminescent substrate (Promega Steady Glo). 
 
Matrigel sponge assay 
The mouse matrigel sponge assay was used to confirm the ability EXN11 to promote 
vascularization on phenotype of different endothelial cell lines. For this purpose, recombinant 
human EXN11 was diluted in unpolymerized liquid Matrigel matrix containing 20 ng/µl of growth 
factors in the presence of heparin 50 U/ml. 350 µl of Matrigel suspension were injected 
subcutaneously into the flanks of 6 week-old Swiss wild type male mice (Charles River) using a 
cold syringe (4 animals group, 2 injections/animal) and allowed to polymerizes at body 
temperature, forming a solid gelatinous sponge. Four days after injection, animals were killed and 
the sponges were removed and photographed to quantify the new vessels formed within the 
sponge. Mice inoculated with the same volume of Matrigel matrix alone were used as negative 
controls. Four sponges were inoculated for each experimental condition. 
 
63 
 
Statistical analysis 
Data are presented as means ± SD from at least three independent experiments. Statistical analysis 
of the data was performed using two-tailed Student’s t-test. P-values ≤ 0.05 were considered 
statistically significant. 
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